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Novelty and Impact: We identified and validated a panel of 74 altered CpG islands, able to discriminate 
CRCs and adenomas from peritumoral and normal mucosa, with very high specificity (100%) and sensitivity 
(99.9%); three selected markers were tested and detected through non-invasive techniques, both in cfDNA 
and in stool DNA. Our results also demonstrated that the earliest methylation alterations affect genes coding 
for proteins involved in the crosstalk between cell and surrounding environment 
  





Colorectal cancer (CRC) develops through the accumulation of both genetic and epigenetic 
alterations. However, while the former are already used as prognostic and predictive biomarkers, 
the latter are less well characterized. Here, performing global methylation analysis on both CRCs 
and adenomas by Illumina Infinium HumanMethylation450 Bead Chips, we identified a panel of 74 
altered CpG islands, demonstrating that the earliest methylation alterations affect genes coding for 
proteins involved in the crosstalk between cell and surrounding environment. The panel 
discriminates CRCs and adenomas from peritumoral and normal mucosa with very high specificity 
(100%) and sensitivity (99.9%). Interestingly, over 70% of the hypermethylated islands resulted in 
downregulation of gene expression. To establish the possible usefulness of these non-invasive 
markers for detection of colon cancer, we selected three biomarkers and identified the presence of 




Colorectal cancer (CRC), the third most prevalent cancer in the world [1], develops over years or 
decades, as a result of the accumulation of genetic and epigenetic alterations. At least three distinct 
types have been described: 1) chromosomal instability (CIN), the most frequent (80-85%), is 
characterized by aneuploidy, chromosomal gains/losses and accumulation of mutations in specific 
oncogenes (e.g. KRAS, PIK3CA, BRAF, etc) and tumor suppressors genes (e.g. APC, SMAD4, 
TP53); 2) microsatellite instability (MSI), caused by dysfunction of DNA mismatch repair genes, 3) 
CpG island methylation phenotype (CIMP), characterized by a widespread CpG island methylation, 
accounting for about 20-40% of CRCs. These types are not mutually exclusive, with tumors 
exhibiting features of more than one [2]. Although CIN tumors are characterized by mutations in 
oncogenes and tumor suppressor genes, epigenetic changes may also play a relevant role in 
neoplastic transformation even at the earliest stages [3-5]. Better knowledge of these epigenetic 
alterations could also help clarify which cellular processes are affected by such early changes and 
drive future functional studies. 
Genes altered by methylation not only might represent potential biomarkers for early detection of 
CRC [6], but could also be important prognostic and predictive markers to improve therapeutic 
interventions [7,8]. Indeed, therapies based on epigenetic reprogramming have been recently tested 
in several types of tumors [9,10]. Moreover, since the screening of epigenetic alterations can also be 
carried out in circulating tumor DNA (ctDNA) and in DNA isolated from faeces of patients at risk 
of CRC, the detection of these biomarkers through less invasive procedures makes their 
identification of great value [8]. 
The aims of the present study were: i) to identify signature alterations in the CRC methylome 
through over 485k CpG loci of CRCs and peritumoral tissues; ii) to test whether these alterations 
represent early events in CRC development; iii) to explore the use of non-invasive techniques (stool 
and ctDNA) to reveal altered methylation. We identified the most altered pathways since early 
stages of CRC tumorigenesis and defined a panel of CpG islands differentially methylated as 
 biomarkers capable to detect CRC even at its earliest stages. This panel was successfully cross- 
validated in silico using methylation data from more than 500 CRC samples. Selected biomarkers 






Materials and methods 
 
Samples collection and processing 
Samples for whole genome methylation analysis 
 
The methylome analysis was first performed in 18 pairs of primary CRCs among which four had 
matched peritumoral samples, taken at a distance of more than 10 cm from the neoplastic tissue 
(selected to represent the four anatomic region affected by cancer: left, right, sigmoid colon, 
rectum). Specimens came from patients diagnosed with CRC and operated at the Department of 
General Surgery, University of Cagliari (Italy) (Figure 1 and Supporting Information Table 1). 
For this study, cases with familial adenomatous polyposis or human nonpolyposis colorectal cancer 
were excluded. 
In a second step, methylome analysis was conducted in 21 adenomas and three matched intestinal 
mucosa controls, from 21 patients bearing an adenoma (Figure 1 and Supporting Information 
Table 2). Lesions were removed during endoscopy [11]. DNA samples were collected at the 
National Institute for Cancer Research of Genoa (Italy). 
Stool samples for methyl-BEAMing analyses 
 
Stool samples were collected from 24 patients with colorectal cancer and taken intraoperatively 
from the bowel resection specimen. All stools samples were immediately frozen after collection and 
stored at −80°C until being processed. DNA extraction was performed using the QIAamp DNA 
Stool Mini Kit according to the manufacturer's instructions. All samples were collected at 
Department of Surgical Sciences, University of Cagliari and Department of Clinical and 
experimental medicine, University of Sassari. (Figure 1) 
Plasma samples for methylBEAMing analyses 
 Blood draws were collected from 45 cases of CRC enrolled at the medical oncology department of 
the Candiolo Cancer Institute-FPO, IRCCS (Torino, Italy) between November 2015 and April 2016. 
Twelve cases were under adjuvant therapy after surgical resection of their lesion and were 
considered with no evidence of disease (NED). Remaining cases (N=33) were metastatic CRC with 
different levels of tumor burden (Figure 1). Whole blood was processed within samples three 
hours after collection. Samples were centrifuged at 1600g for 10 minutes for phase separation. 
Plasma was collected and submitted to a second centrifugation step at 3000g for 10 minutes to 
remove platelets and cell debris. Upper phase was collected, aliquoted and stored at -80°C until 
further processing. One milliliter of plasma was processed for DNA extraction using the Maxwell® 
RSC ccfDNA Plasma Kit (Promega) using 100µl for the elution volume. 
Samples for Real-Time qRT-PCR validation 
 
A total of 26 RNA samples (eight CRC with matched peritumoral tissues and ten individual CRCs), 
extracted as described in the previous paragraph, were tested by qRT-PCR (Figure 1). 
DNA extraction and bisulfite conversion from tissue samples 
 
Genomic DNA was extracted from tumoral and peritumoral tissue using the DNeasy Blood & 
Tissue Kit (Qiagen) and bisulfite converted using EZ DNA Methylation Gold Kit ™ (Zymo 
Research) according to the manufacturer's instructions. Quality control and quantification of DNA 
were performed before and after bisulfite conversion. Further details are available on supplementary 
materials. 
DNA methylation assay 
 
Four microliters of bisulfite-converted DNA were used for hybridization on Infinium 
HumanMethylation 450 BeadChip (450K), following the Illumina Infinium HD Methylation 
protocol. Data were acquired on an Illumina HiScan SQ scanner. Image intensities were extracted 
using GenomeStudio (2010.3). 
MethylBEAMing analysis 
 
The primers used for pyrosequencing were coupled with Tag sequence as previously described [9]. 
Two microliters of bisulfite converted cfDNA was amplified in replicate and processed following 
the same protocol previously described [10]. (Supporting Information Table 3). 
 Purified beads were run on a BD Accuri C6 (Becton-Dickinson), methylation percentage was 
expressed as the number of events in the methylated gate divided by the sum of events in 
methylated and unmethylated gates multiply by 100. 
Markers selection for validation of locus specific methylation alterations 
 
We selected three CpG islands, based on both a large methylation Δ between tumor and non-tumor 
tissue and the feasibility of the assay. Thirteen regions belonging to the biomarker panel identified 
were selected for locus specific investigation. Since cell free circulating and stool DNA is known to 
be composed of short fragments [12], significant probes which were distant from a maximum of 
150bp (defining 23 loci) were selected to assess their potential to discriminate tumors from normal 
tissue in The Cancer Genome Atlas (TCGA) COREAD cohort using ROC analyses. Ten loci 
demonstrated a positive predictive value of 1 and a negative predictive value of at least 0.5. Among 
those, three regions allowed methylation independent amplification assay with highly specific probe 
design (GRIA4, SLC8A1, SYN3) (Supporting Information Table 4) and were firstly validated in a 
second data set of 78 tumoral and matched peritumoral tissue samples by pyrosequencing analysis 








The power was estimated on the calculation of the parameters of interest using the GSE48684 
dataset. Based on this preliminary data the number of samples was calculated assuming an effect 
size that consider a differential methylation level of at least 10%, using a type I error of 10e-8 
(which takes into account the need to correct for multiple test) and a statistical power of 0.8. Using 
these criteria, the number of samples to be analyzed should be 30. 
Methylome data management 
 
Illumina Methylation 450K raw data were analysed using the RnBeads analysis software package, 
as previously described [13,14]. In addition to CpG sites, four sets of genomic regions were covered 
in the analysis (tiling, genes, promoters and CpG Islands). Corrected p values (Benjamini & 
Hochberg) were computed as previously described [13,14]. The selected differently methylated 
 CpG loci were annotated, by referring to the 450k manifest, in order to obtain a gene list based on 
HGNC database. The beta values obtained for each sample at each CpG locus analyzed, were used 
in an analysis of Unsupervised Hierarchical Clustering (UHC), that, comparing locus to locus, 
allows to trace a tree (called dendrogram) whose closest branches indicate the most similarity in the 
methylation pattern, and vice versa. Finally, beta values were also visualized by building a 
HeatMap. 
Biomarker specificity and sensitivity evaluation 
 
We evaluated in three datasets (discovery set, GSE48684, TCGA COREAD) the tumoral and non- 
tumoral beta value distribution relative to the 74 biomarkers. The combined p-value of each 
biomarker was obtained using the Fisher’s method, by combining the p-value of each CpG site 
belonging to a particular CpG island, calculated using the Wilcoxon test. 
To evaluate the association of each biomarker with a binary outcome a logistic regression model 
was fitted to the individual biomarker data and the new probabilities used to calculate the area under 
the curve (AUC), specificity and sensitivity values using the “OptimalCutpoints” package [15]. 
To evaluate the ability of the entire biomarkers panel to correctly classify between two possible 
conditions (i.e tumoral vs. non-tumoral), we built a support vector machine learning model (SVM), 
using the GSE48684 dataset as a training set and the TCGA COREAD as test set and evaluate the 




Functional annotations of the differently methylated loci, were conducted by the ToppGene package 
[16], from which are derived the information on the pathways potentially involved. The significance 
value was corrected for multiple comparisons (Bonferroni or Benjamini & Hochberg). 
 
Three cross-validation datasets were retrieved from the database NCBI Gene Expression Omnibus 
(GEO) portal (http://www.ncbi.nlm.nih.gov/geo/) under accession numbers GSE48684, GSE52270, 
GSE53051. Processed data were used for all datasets above mentioned. TCGA COREAD cohort is 
available online at RnBeads website under Methylome Resources (http://rnbeads.mpi-  
inf.mpg.de/methylomes.php). For each of these datasets the mean methylation value for each CpG 





All the biological samples analysed were obtained with written informed consent signed from 
patients and ethical approval granted by the relative Ethics Committee: CRC tissue samples by the 
Independent Ethics Committee of the University Hospital of Cagliari; stool samples by the 
Independent Ethics Committee of the University Hospital of Cagliari and by Comitato Bioetico 
della Azienda Sanitaria Locale di Sassari; Plasma samples by the Ethical Committee of the IRCCS 





CRC methylome alterations are early events in colon carcinogenesis: identification of an early 
epigenetic biomarkers panel 
The differential methylation analysis conducted on 18 CRCs and 4 peritumoral samples (Figure 1 
and Supporting Information Table 1), powerfully discriminated tumor samples from peritumoral 
tissues. We identified 22307 CpG loci differentially methylated with an adjusted p-value threshold 
of 0.05 (Benjamini & Hochberg multiple test correction). To test whether these alterations represent 
an early event in carcinogenesis, we conducted a differential methylation analysis on 21 adenomas 
vs. 3 control mucosae (Figure 1 and Supporting Information Table 2). As expected, the results of 
the analysis in adenomas were less robust than in CRCs. Using the nominal threshold (p-value 
<0.05), 43999 CpG loci resulted differently methylated. In both CRCs and adenomas, a wide 
hypomethylation of the tumoral samples was found by analyzing the entire genome, divided into 
portions (tiling), however, by restricting the analysis to the regulatory regions, a switch towards 
hypermethylation, especially in the CpG islands, was evident (Figure 2A and 2B). 
The list of genes whose associated CpG islands, were significantly altered (875 in CRCs and 2393 
in adenomas), was subjected to a gene enrichment and candidate gene prioritization analysis by 
Toppgene, allowing the identification of the pathways most affected by aberrant methylation: Wnt 
signaling, Neuronal System, Cadherin signaling, Transmission across Chemical Synapses, 
Neuroactive  ligand-receptor  interaction,  Neurotransmitter  Release  Cycle,  GABAergic  synapse, 
 Core extracellular matrix, Calcium signaling, Cholinergic synapse (Supporting Information Table 
5). For the list of the 171 genes found modified in CRCs and 432 in adenomas belonging to 10 
significantly involved pathways, see Supporting Information Table 6. Notably, Toppgene results 
show that the most affected pathways were largely comparable between CRCs and adenomas 
(Figure 2C). 
Remarkably, most of the genes whose associated CpG islands were altered in CRCs, were “already” 
aberrant in adenomas. In Figure 3 and Supporting Information Table 7 are listed 74 CpG islands 
resulting from the comparison, with the respective average beta values and s calculated between 
the average value in the tested samples (CRCs or adenomas) and in the respective controls. 
Interestingly, only two islands, at GNG7 and GRIN3B genes, underwent hypomethylation in both 
adenomas and CRCs. Of note, the  average beta value was always higher in CRCs than in 
adenomas (except for EDNRB), probably due to a greater methylation heterogeneity among 
adenomas. Surprisingly, none of the genes listed in Figure 3 resulted dysregulated by the 
transcriptome analysis. However, all those genes displayed an extremely low level of expression, 
close to the background intensity level. Therefore, an investigation by qRT-PCR was undertaken 
(Supporting Information Figure 1). UHC was conducted on the CRCs and adenomas (Figure 3) 
discovery set, based on the 74 biomarkers panel. A multi-cluster gene functional  enrichment 
analysis conducted only for the genes associated to the 74 CpG islands, showed a significant 
enrichment of proteins involved in the crosstalk between cell and surrounding environment (see 
Figure 3 and Figure 4). 
In silico validation of the CRC early biomarkers panel: specificity for primary tumors and 
metastases 
To validate and increase the statistical power of our discovery dataset results, first, we cross- 
validated in silico our set of markers, as predictors of cancer and adenoma, using methylation data 
from two databases: I) TCGA COREAD cohort [18] (Figure 5A); II) GSE48684 [3](Figure 5B). 
The 74 biomarker panel was able to separate most carcinomas and adenomas from normal mucosa. 
ROC analysis was performed for each marker using TCGA COREAD cohort. The specificity of 
many markers was equal to 1, i.e. 100% (ranging from 0.89 and 1), the sensitivity was ≥ 0.9 in over 
70% of the islands (ranging from 0.7 and 0.97) (Supporting Information Table 7 and Supporting 
Information Table 8). The robustness of the identified biomarkers was supported by p-values 
lower than the threshold for claiming genome-wide significance (P < 10-8). We also evaluated the 
 specificity, sensitivity, AUC and accuracy for the entire panel, obtaining respectively: SP = 1; SE = 
0.9942; AUC = 1; ACC = 0.9971. 
To verify if the panel is specific for CRC, we examined the GSE52270 data set [19]. The panel 
resulted specific for CRC, but not for the other analyzed cancer types (Figure 5C). 
Interestingly, the UHC of our CpG islands panel in a fourth data set (GSE53051) [20], assigned 
colon cancer metastases on the same branches of CRC, with the exception of two cases (Figure 
5D). These results suggest that these alterations are not counter-selected during carcinogenesis and 
are maintained in metastases. 
Methylation analysis in stool DNA samples 
 
Based on the consistency of the methylation alterations identified in the tumor tissues, we wondered 
whether these methylation patterns could be detected in DNA extracted from stools. The goal was 
to set up in CRC patient stools the experimental test as a possible non-invasive technique to detect 
early/asymptomatic CRCs. We selected three CpG islands, associated to GRIA4, SLC8A1 and SYN3 
genes, based on both a large methylation Δ between tumor and non-tumor tissue and the feasibility 
of the assay experimental design (Supporting Information Table 4). To assess the reproducibility 
of the three selected markers, we performed a methylation analysis by pyrosequencing in a second 
data set of 78 tumoral and 78 matched peritumoral samples (Figure 1). All three selected islands, 
associated to GRIA4, SLC8A1 and SYN3 genes, were significantly hypermethylated in tumor vs. 
peritumoral samples (Supporting Information Figure 2). Methylation of the same CpG islands, 
was thus assessed, by digital PCR analyses, in DNA isolated from CRC patients’ stool samples, 
taken at the time of surgical resection. As shown in Figure 6A, all except three tested samples 
(87.5%) showed more than 1% of methylation for at least one of the three markers. In particular, 
79.2% of samples showed more than 1% of methylation at GRIA4 (average 21%); 70.8%  at 
SLC8A1 (average 10%); 62.5% at SYN3 (average 13%). 
Methylation analysis in ctDNA 
 
Tumor fragments of DNA in the blood stream can be used as a surrogate sample to tissue biopsy. 
Cell free circulating DNA is a mixture of nucleic acids from normal (mainly from leukocytes) and 
from tumor tissues (ctDNA) [21] Liquid biopsy test using genetic or epigenetic alterations in 
plasma DNA has been proposed for early diagnosis [6] and early detection of relapse [22-24]. 
Methylation of GRIA4, SLC8A1 and SYN3 was assessed in circulating DNA of CRC patients. 
Assays were successful in at least one replicate for 43, 45 and 41 cases for GRIA4, SLC8A1 and 
SYN3, respectively. Some patients were receiving adjuvant therapy post-surgical resection of their 
 tumor with no radiologic evidence of disease (NED) and were expected to display very low or no 
ctDNA. The aim of these exploratory analyses was to compare methylation levels at the three loci 
between NED and patients still bearing a lesion. Median methylation at GRIA4 and SLC8A1 was 
significantly different (u-test, GRIA4: p-value =0.029; SLC8A1: p-value =0.024). SYN3 did not 
show any difference, possibly due to low number of cases which displayed methylation. The 
positivity exclusively seen in patients with lesions demonstrates the specificity of the selected 
markers. 
Among clinical features (Supporting Information Table 9), CEA levels, a surrogate of tumor 
burden, could discriminate two subgroups among the patients still bearing a lesion. According to the 
literature, we divided the samples into three groups: NED, CEA-low and CEA-high, using a 
threshold of 5 ng/ml; indeed, CEA elevation over 5 ng/ml was found to be a very accurate marker 
of recurrence [25]. As shown in Figure 6B, dividing the samples in the three groups, did not result 
in significant differences between NED and CEA-low, relatively to the observed methylation levels, 
while significantly higher methylation levels (p-value = 0.00223 and p-value = 0.01972, 
respectively) were evident for GRIA4 and SLC8A1 in the CEA-high group. Of note, patients with 
low CEA whose primary tumor was mutated for RAS or BRAF, did not display the genetic alteration 
in ctDNA (Figure 6C). Interestingly, the three NED subjects with high levels of CEA, did not show 






The genetic and epigenetic landscape of CRC has been extensively studied so far. However, current 
technological advances in DNA methylation analysis have enabled the identification and validation 
of new biomarkers in a more unbiased way. Nevertheless, the concept of CIMP phenotype remains 
debated [26], mostly due to lack of consensus in its evaluation warranting unbiased genome-wide 
approaches to characterize epigenetic changes involved in CRC onset and development [4]. We 
observed limited correlation between CIMP phenotype and hypermethylation of the CpG islands 
included in our panel, perhaps because we selected loci as being the most informative on the early 
 alterations, or perhaps because CIMP was classically defined on methylation alterations discovered 
before the advent of genomic approaches to assess global methylome. 
Although several studies have been conducted analysing methylome alterations in CRCs, there is 
still urgent need for biomarker discovery. In our work, we identified a panel of 74 CpG islands 
aberrantly methylated not only in advanced stages of disease, but already detectable in adenomas, 
when the tumor is often asymptomatic. The performance ability of the panel was cross-validated in 
silico by analysing it in hundreds of samples, including CRCs, adenomas, normal counterparts and 
other tumor types. The identified panel appears very robust and informative (sensitivity 99.99%), 
specific for CRC (specificity 100%) from early to metastatic stages. Multiple studies have 
investigated the use of single or combined DNA methylation-based biomarkers for diagnostic 
purposes [8]. The performance ability of SEPT9 and VIM, the only two commercially available 
methylation biomarkers, to identify CRC/adenomas greatly varies depending on the experimental 
design. However, combining both the markers into a panel could improve the diagnostic accuracy 
and achieve higher clinical sensitivity. Not only our results are consistent with this observation but 
the performance ability of most of our biomarkers outperforms that of commercially available ones. 
Importantly, this set of markers could be detected in CRC patients even through non-invasive 
techniques, as we identified hypermethylated tumoral DNA both in stool and plasma samples of 
CRC patients. Overall, the panel shows a good diagnostic and prognostic value even in the non- 
invasive assessment, strengthening its potential value in screening and follow-up of CRC patients. 
Previously, three selected markers (AGTR1, WNT2, SLIT2) were validated in stool DNA samples 
from CRC patients, showing a sensitivity of 21%, 40% and 52% respectively [27]. A panel of these 
genes reached a sensitivity of 78%, based on the criteria that at least one of the genes was 
methylated. In comparison, our three selected biomarkers performed better in terms of sensitivity, 
with a percentage of samples showing more than 1% of methylation, ranging from 62.5% to 79.2%. 
Based on a similar criterion, the panel of our selected markers guaranteed an overall sensitivity of 
87.5%. We conclude that, even in these samples, the tested CpG islands resulted excellent tumor 
markers despite the technical difficulties related to a biological challenging matrix, such as stool. 
Nevertheless, we acknowledge the exploratory nature of our analyses in a limited stool dataset from 
patients who had already received a CRC diagnosis. Future studies are warranted to assess the 
sensitivity and specificity of the loci identified in this work in stool DNA from asymptomatic 
individuals and early stage disease. 
 Concerning cell free DNA samples, two markers (GRIA4 and SLC8A1), were able to distinguish 
NED patients from metastatic and CEA-low from CEA-high. Indeed, methylation alterations 
displayed a negative predictive value higher than CEA (as demonstrated by the three NED patients 
with elevated CEA levels but not hypermethylated DNA). The absence of alterations observed in 
the low-CEA subgroup might be due to specific biologic features of these tumors, impairing the 
release of circulating markers (e.g.: well differentiated status of neoplastic cells, absence of vascular 
network, etc.). On the other hand, the limited sensitivity of the techniques employed to assess 
methylation could have yielded false negative results. Indeed, we acknowledge that the current 
digital PCR technique may have limited sensitivity for cases with low tumor burden, since the 
assays was designed for monitoring purposes (not early detection) privileging highly linear 
quantification, instead of high sensitivity [28]. Further assay improvements are therefore warranted 
for the early detection setting. Moreover, studies with larger number of patient plasma samples and 
controls from healthy individuals are required to establish and exploit the potential of our markers 
in liquid biopsies. 
In addition to identifying potentially new powerful biomarkers (only partially already correlated to 
cancer, see Supporting Information Table 10), in CRC early diagnosis and traceability of minimal 
residual disease, this study has highlighted the biological processes mainly affected by early 
methylation alterations in colon carcinogenesis. In fact, as shown in Figure 4, the crosstalk between 
tumor cells and surrounding environment resulted particularly involved, in terms of membrane 
receptors, solute transporters and cell adhesion molecules. Functional annotation analysis has 
highlighted the enrichment of protocadherins [29-33], integrins [34], members of the solute carrier 
family [35-40], and, extensively, G-protein coupled receptors involved in the transduction of 
neuroactive signals [41,42]. 
Silencing of genes coding for protocadherins (PCDHs) by means of promoter hypermethylation, 
such as PCDH10 in different carcinomas [29,30] and PCDH8 in breast cancer [31], has been shown 
in several cancer types. In particular, it has been demonstrated that a cluster of PCDHs located on 
chromosome 5q31 undergoes a mechanism of long range epigenetic silencing (LRES) by 
hypermethylation [32]. PCDH LRES was described in Wilms tumor [32], breast [43] prostate [44] 
and colorectal cancer [45], suggesting a tumor suppressor role of this protocadherin cluster in 
several types of cancer. As other LRES loci have been identified in breast [43], head and neck [46], 
lung [46], prostate [33] and colon cancer [47], silencing of tumor suppressor genes by this 
mechanism to appears a emerges as a common feature in human cancer [33]. 
 The list of genes reported in Supporting Information Table 7 also highlights the involvement of 
several carriers, including many members of the solute carrier family (SLC). These genes, unlike 
PCDHs, are located on different chromosomes, but their common alteration suggests a 
combinatorial control, a mechanism well known in the regulation of gene expression. Indeed, 
methylation-mediated silencing of solute carriers was already reported in CRC, lung, prostate 
(SLC5A8) [35-37], breast and gastric cancers (SLC19A3) [38,39] and gliomas (SLC22A18) [40]. 
Functional studies will clarify the role of the epigenetic alterations identified in the present study, 
especially considering that over 70% of hypermethylated islands resulted in downstream 
downregulation (Supporting Information Figure 3). Remarkably, almost all these molecules are 
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Figure 1: Project workflow and description of sample sets used for the different working 
stages  
Discovery sets: CRC and adenoma DNA samples collected for the study of methylome (450K), 
transcriptome (HT-12) and gene expression by qRT-PCR. In silico validation sets: data used to 
validate the identified biomarkers panel and for the evaluation of RNA-Seq (TCGA data set). 
Screening / wet validation sets: samples used for locus-specific methylation alterations in a further 
collection of tissues (tumor and peritumoral), stool samples and in the plasma of patients suffering 
from CRC. 
Figure 2: Differential methylation and functional annotation analyses results obtained from 
the discovery data set methylome study 
A) RnBeads differential methylation analysis performed on the data obtained using Infinium 
HumanMethylation 450 BeadChip, for single CpGs and for sets of pre-defined genomic regions 
such as genome-wide 5kb tiling regions, genes, promoters and CpG islands, in CRC vs. peritumoral 
tissue samples. Each dot represents the average beta value (methylation value) for each CpG locus 
in the region, resulting from the average of the samples belonging to that group; in red are those 
significantly differentially methylated. The pathways significantly altered are shown (in descending 
order of significance), according to the functional annotation analysis performed by ToppGene 
package. This analysis was conducted on the genes corresponding to the CpG islands significantly 
altered, according to the 450K manifest. The outputs generated by ToppGene show: the number of 
genes belonging to the pathway, the number of altered genes belonging to the pathway, and 
significance levels, raw and corrected for multiple testing according to Bonferroni and to Benjamini 
& Hochberg. 
 
B) RnBeads differential methylation analysis performed in adenomas vs. normal mucosa samples. 
 
C) The most significantly altered pathways are also shown, according to the functional annotation 
analysis performed by ToppGene. Circos plot resulting by the comparison of pathways significantly 
altered in CRC (left) and adenomas (right). For each pathway, identified by a number (whose 
correspondence is given in the supplementary material), are given the number of genes involved 
and the relative frequency. The red arrow indicates the pathways which show significant enrichment 
 of altered loci (decreasing p value) in CRC; the blue arrow in adenomas. The name of the five 
pathways most significantly altered in CRC are given and highlighted in color. Colored beams link 
the shared genes. The pathways significantly altered, obtained by functionally annotating the entire 
list of genes altered in CRC and adenomas, are also shown.  
 
Figure 3: Discovery set unsupervised hierarchical clustering analysis based on the average 
methylation beta value for each of the 74 CpG islands 
Heat map obtained by UHC of CRCs, adenomas, peritumoral tissue and normal mucosa samples. 
To the right of the heat map the genes associated to the 74 CpG islands aberrantly methylated and in 
common between CRC and adenomas are listed. All CRCs grouped on a branch separated from 
peritumoral and normal mucosa samples, with the sole exception of samples 352T and 279T.While 
seven adenomas branched along with peritumoral and normal mucosa samples, the remaining ones 
closely resembled the methylation pattern of carcinomas. Peritumoral and normal mucosa samples 
show an extremely similar pattern. No correlation trend was observed between methylation patterns 
and staging, localization or mutational pattern in both CRCs and adenomas. Other information 
reported: MS, microsatellites stability or instability; APC and KRAS mutational status; CIMP like, 
CIMP status as defined in the Supplementary methods; histology, Dukes tumoral staging, adenomas 
grade; localization. 
Figure 4: Network visualization of multi-cluster gene functional enrichment analysis 
performed by Toppcluster tool on the genes associated to the 74 biomarkes 
In green squares: pathway annotation. In blue squares: GO: molecular function annotation. In red 
hexagons: gene set. 
Figure 5: In silico validation, by unsupervised hierarchical clustering analysis, of the early 
biomarkers panel in different data sets 
A) Heat map of TCGA COREAD cohort: 248 colon and 94 rectum adenocarcinomas, 37 colon and 
7 rectum normal tissues. 
B) Heat map of GSE48684 data set: 42 adenomas, 64 carcinomas and 41 normal mucosa from 
colon. It is evident that the biomarkers panel was able to separate the majority of carcinomas and 
adenomas from normal mucosa, while no correlation between the methylation degree and tumor 
staging or location could be observed. 
C) Heat map of GSE52270 data set: 103 CRC samples, 18 colon peritumoral tissues, 66 breast 
 cancers and 19 no-tumoral breast tissues, 48 glioblastomas and 10 white matter samples. The 
biomarkers panel is specific for colorectal cancer, but not for the other analyzed cancer types, with 
rare exceptions only for few markers. 
D) Heat map of GSE53051 data set: 9 CRC samples, 18 colon peritumoral tissues, 10 adenomas, 16 
colon cancer metastases, 14 breast cancers and 10 no-tumoral breast tissues, 9 lung cancer and 11 
no-tumoral lung tissues, 29 pancreas cancer and 12 no-tumoral pancreas tissues, 70 thyroid cancer 
and 13 no-tumoral thyroid. Colon cancer metastases localized in the lung and in the liver are on the 
same branches of CRC, with the exception of two cases. 
Figure 6: Validation of GRIA4, SLC8A1 and SYN3 specific methylation alterations in tissues, 
stool DNA samples and cfDNA 
A) MethylBEAMing analysis results obtained for GRIA4, SLC8A1 and SYN3 in DNA isolated from 
stool samples of CRC patients, taken at the time of surgical resection. Colored bars show the 
methylation percentage at the three islands, cumulated for each sample. 
B) MethylBEAMing methylation values in cfDNA, isolated from plasma, for GRIA4, SLC8A1 and 
SYN3. Samples were divided into three groups: NED, CEA-low and CEA-high, using a threshold of 
5 ng/ml. c) Graph showing the percentages of genetic and methylation alterations detected in 
plasma (left Y axis) and CEA levels (right Y axis) for all samples, divided into NED, CEA-low and 
CEA-high. 
All shown comparison were performed using Mann-withney U-test. Asterisks indicate the 
significance level: * = p value <0.05; ** = p value <0.01; *** = p value <0.001. 
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Supporting Information Figure 1: Validation of changes in gene expression observed by WGGE 
analysis 
A) Validation of changes in gene expression observed by WGGE analysis, evaluated by qRT-PCR on three 
selected genes: ADH1A (Alcohol Dehydrogenase 1A), CA1 (Carbonic Anhydrase I), and GCG (Glucagon). 
For each gene is shown the fold change of 8 peritumoral (P) and 18 tumor (T) samples, of 8 matched pairs 
(P / T), and the average of P versus T.  
B) Colorectal adenoma (left) and carcinoma (right) tissues, immunostained for CA1. 
 Supporting Information Figure 2: Pyrosequencing validation of GRIA4, SLC8A1 and SYN3 specific 
methylation alterations in a second data set of tumoral and peritumoral tissues 
Pyrosequencing methylation analysis of three selected islands, related to the GRIA4, SLC8A1 and 
SYN3 genes, performed in a second data set of 78 tumoral and 78 peritumoral samples. On the Y 






Supporting Information Figure 3: Differential gene expression and functional annotation analyses  
A) Heat map showing the results of an unsupervised hierarchical clustering analysis performed on the 
average intensity values obtained from the WGGE analysis on the discovery CRC and peritumoral tissue 
samples sets. WGGE analysis was conducted using the HumanHT-12 v4 Expression BeadChip. As 
expected, all CRCs grouped on a branch separated from peritumoral samples. The results of the differential 
expression analysis, showed the presence of 963 significantly dysregulated transcripts (329 downregulated, 
171 upregulated, using a cutoff value of |FC| > 2), some of which were also validated by qRT-PCR and at 
the protein level by immunostaining (Supporting Information Figure 1).  
B) Pathways resulting dysregulated by functional annotation of genes differentially expressed in the WGGE 
analysis, performed by ToppGene package. The analysis showed that the most altered pathways were 
involved in biological oxidation processes. The highlighted pathways did not overlap with those of the 
methylome (compare Supporting Information Table 5), apart from those relating to the extracellular 
matrix. A number of down-regulated pathways (such as those involved in amines degradation) are likely 
downstream of those modified as a consequence of hypermethylation.  
C) Functional validation of CpG islands hypermethylation as target genes downregulation, evaluated by 
qRT-PCR on three selected genes: GRIA4 (glutamate receptor, ionotropic, AMPA 4), SCTR (secretin 
receptor), and VIPR2 (vasoactive intestinal peptide receptor 2). For each gene is shown the fold change of 8 
peritumoral (P) and 18 tumor (T) samples, of 8 matched pairs (P / T), and the average of P versus T. All the 
three tested genes were significantly down-regulated in cancer.  
D) TCGA CRC RNAseq data corresponding to the gene neighbors the 74 selected altered CpG islands. The 
X axis shows the expression fold change value; along the Y axis the average value of differential 
methylation for each CpG island. In blue, CpG islands included in promoter regions (according to the 
definition given in Methods), in purple those not falling into promoters. More faded the symbols 
corresponding to the CpG islands showing a not significant fold change (between -2 and +2). Almost all the 
selected altered CpG islands were located in the promoter region of genes (defined as the sequence between 
2kb upstream and 1kb downstream the TSS), and the majority of them (> 70%) were associated to down-
regulation of the corresponding genes in the tumor tissues. The only islands associated to the three genes 
strongly upregulated, are actually not located into their promoter regions but in the gene body or 
downstream. 
 
Supporting Information Table 1: CRC Discovery Set 
 





254_P Wt Wt 
 
Peritumoral CIMP_neg Left Colon Yes Yes Yes 
264_P Wt Wt 
 
Peritumoral CIMP_neg Sigmoid colon Yes No Yes 
279_P Wt Wt 
 
Peritumoral CIMP_neg Rectum Yes Yes Yes 
313_P Wt Wt  Peritumoral NA NA No Yes Yes 
325_P Wt Wt  Peritumoral NA NA No Yes Yes 
352_P Wt Wt  Peritumoral NA NA No No Yes 
359_P Wt Wt 
 
Peritumoral CIMP_neg Right Colon Yes No Yes 
402_P Wt wt  Peritumoral NA NA No no Yes 
254_T Wt Wt b CRC CIMP_neg Left Colon Yes Yes Yes 
264_T Wt Wt b CRC CIMP_neg Sigmoid colon Yes Yes Yes 
279_T Mutated Wt d CRC CIMP_neg Rectum Yes Yes Yes 
308_T Wt Wt b CRC CIMP_neg Sigmoid colon Yes Yes Yes 
309_T Wt Wt a CRC CIMP_neg Sigmoid colon Yes Yes Yes 
310_T Wt Wt a CRC CIMP_pos(>20%) Left Colon Yes Yes Yes 
311_T Wt Mutated a CRC CIMP_neg Rectum Yes Yes Yes 
313_T Wt Wt b CRC CIMP_pos(>20%) Sigmoid colon Yes Yes Yes 
325_T Wt Wt d CRC CIMP_neg Rectum Yes Yes Yes 
337_T Wt Wt d CRC CIMP_pos(>20%) Left Colon Yes Yes Yes 
352_T Wt Wt d CRC CIMP_neg Sigmoid colon Yes Yes Yes 
359_T Mutated Wt b CRC CIMP_pos(>30%) Right Colon Yes Yes Yes 
362_T Wt Wt a CRC CIMP_neg Rectum Yes Yes Yes 
368_T Mutated Wt b CRC CIMP_neg Sigmoid colon Yes Yes Yes 
376_T Wt Mutated b CRC CIMP_pos(>30%) Right Colon Yes No Yes 
400_T Mutated Wt d CRC CIMP_neg Rectum Yes Yes Yes 
402_T NA NA NA CRC NA NA No No Yes 
407_T Mutated Wt d CRC CIMP_neg Sigmoid colon Yes Yes No 
455_T Wt Wt d CRC CIMP_neg Sigmoid colon Yes Yes Yes 
 
Supporting Information Table 2: Adenomas Discovery Set 
 
Sample KRAS APC Grade Histology CIMP_like Anatomic site 
CTE1279 Wt Wt 
 
Normal CIMP_neg Right Colon 
CTE1434 Wt Wt 
 
Normal CIMP_neg Left Colon 
CTE1620 Wt Wt 
 
Normal CIMP_neg Left Colon 
CTE1266 Wt Mutated Adenoma_mild_dysplasia Adenoma CIMP_neg Left Colon 
CTE1280 Mutated Wt Adenoma_mild_dysplasia Adenoma CIMP_pos(>30%) Right Colon 
CTE1435 Mutated Wt Adenoma_severe_dysplasia Adenoma CIMP_neg Left Colon 
CTE1470 Wt Wt Adenoma_low_dysplasia Adenoma CIMP_neg Left Colon 
CTE1473 Mutated Wt Adenoma_mild_dysplasia Adenoma CIMP_neg Left Colon 
CTE1474 Mutated Wt Adenoma_mild_dysplasia Adenoma CIMP_neg NA 
CTE1540 Wt Wt Early cancer in adenoma Adenoma CIMP_neg Left Colon 
CTE1619 Wt Wt Adenoma_mild_dysplasia Adenoma CIMP_neg Left Colon 
CTE1621 Wt Mutated Adenoma_severe_dysplasia Adenoma CIMP_neg Left Colon 
CTE1727 Wt Mutated Early cancer in adenoma Adenoma CIMP_neg Left Colon 
CTE1730 Wt Wt Early cancer in adenoma Adenoma CIMP_neg Left Colon 
CTE1748 Mutated Wt Early cancer in adenoma Adenoma CIMP_neg Left Colon 
CTE1877 Wt Wt Early cancer in adenoma Adenoma CIMP_neg Left Colon 
CTE2032 Wt Wt Adenoma_mild_dysplasia Adenoma CIMP_neg Left Colon 
CTE2034 Wt Mutated Adenoma_low_dysplasia Adenoma CIMP_neg Left Colon 
CTE2035 Wt Wt Adenoma_low_dysplasia Adenoma CIMP_neg Right Colon 
CTE2036 Wt Wt Hyperplastic polyp Adenoma CIMP_neg Left Colon 
CTE2040 Wt Wt Adenoma_low_dysplasia Adenoma CIMP_neg Left Colon 
CTE2046 Wt Wt Adenoma_severe_dysplasia Adenoma CIMP_neg Right Colon 
CTE2052 Wt Wt Adenoma_low_dysplasia Adenoma CIMP_neg Left Colon 
CTE2055 Wt Wt Hyperplastic polyp Adenoma CIMP_neg Left Colon 
 
 
Supporting Information Table 3: List of primers and probes used in the present study 
Assay Gene Primer/Probe Sequence (5’-3’) 
Genetic mutations screening KRAS (exon 2) Forward ACTGGTGGAGTATTTGATAGTGTAT 
 
 Reverse AGAATGGTCCTGCACCAGTAA 
 
KRAS (exon 3) Forward TCCAGACTGTGTTTCTCCCT 
 
 Reverse AACCCACCTATAATGGTGAATATCT 
Pyrosequencing analysis SYN3 Forward [btn]TTGGGTAGGTTTTTGGGATAGATAG 
 
 Reverse ATAAAAACAATCTTAAAATCCACAAT 
 
 Sequence ACAATCTTAAAATCCACAATC 
 
SLC8A1 Forward TTTGGGGAAAGATTTTAGGGATTA 
 
 Reverse [btn]AAAATCCAAACCTCCCCACCCACT 
 
 Sequence GGGAAAGATTTTAGGGATTAT 
 
GRIA4 Forward GGGTTGGTGTAGGTTTGTT 
 
 Reverse [btn]CTCCCCCCTTACTTTCTCACATACACACAA 
 
 Sequence GTGTAGGTTTGTTGGG 
MethylBEAMing analysis SYN3 Forward TCCCGCGAAATTAATACGACTTGGGTAGGTTTTTGGGATAGATAG 
 
 Reverse GCTGGAGCTCTGCAGCTAATAAAAACAATCTTAAAATCCACAAT 
 
 met-probe /5Alex647N/GACAAACGACCCCCGCACG 
 
 unm-probe /5Alex488N/CAACAAACAACCCCCACACA 
 
SLC8A1 Forward TCCCGCGAAATTAATACGACTTTGGGGAAAGATTTTAGGGATTA 
 
 Reverse GCTGGAGCTCTGCAGCTAAAAATCCAAACCTCCCCACCCACT 
 
 met-probe /5Alex647N/GCGAACATCCCTCCTTCCG 
 
 unm-probe /5Alex488N/ACAAACATCCCTCCTTCCA 
 
GRIA4 Forward TCCCGCGAAATTAATACGACGGGTTGGTGTAGGTTTGTT 
 
 Reverse GCTGGAGCTCTGCAGCTACTCCCCCCTTACTTTCTCACATACACACAA 
 
 met-probe /5Alex647N/AACGCCGCGACCGCCACAC 
 
 unm-probe /5Alex488N/CACCACAACCACCACACACA 
qRT-PCR analysis SCTR Forward GGATGGTGGAGGTGGAATG 
 
 Reverse AAGGTTTCTGACCAGCCATC 
 
VIPR2 Forward  GTCTCTTGCAACAGGAAGCA 
 
 Reverse TCTCAGGATGAAGGACAGGAA 
 
GRIA4 Forward TCATGTGGACAACATTGAGACA 
 
 Reverse ATCATAGAGTCCAAAAATGGCAAA 
 
ADH1A Forward TGGAGGTGTGGATTTTTCATT 
 
 Reverse CCCTACGATGACACTTGTGC 
 
CA1 Forward CAGTACAAATGAGCATGGTTCAG 
 
 Reverse GCAAGGCTGGAGTACTTTGC 
 
GCG Forward CCAAGATTTTGTGCAGTGGTT 
 
 Reverse GGTAAAGGTCCCTTCAGCAT 
 
TFRC (endogenus) Forward GGCACAGCTCTCCTATTGAAAC 
 
 Reverse CAAAGTCTCCAGCACTCCAACT 
Supporting Information Table 4: Markers selection for validation of locus specific methylation alterations 
 
 Chromosome Start End Threshold Specificity Sensitivity npv ppv 
ADAMTS2-A chr5 178771329 178771394 0.313 0.956 0.923 0.573 0.995 
ADAMTS2-B chr5 178771776 178771782 0.229 1.000 0.908 0.542 1.000 
ADAMTS2-C chr5 178772372 178772391 0.147 1.000 0.851 0.421 1.000 
CREB5-D chr7 28449847 28450002 0.305 1.000 0.918 0.570 1.000 
CRHR2-E chr7 30722114 30722178 0.155 1.000 0.884 0.484 1.000 
CRHR2-F chr7 30722320 30722362 0.335 1.000 0.884 0.484 1.000 
GRIN2D-G chr19 48947560 48947632 0.333 0.933 0.969 0.764 0.993 
HTR1E-H chr6 87647370 87647528 0.393 1.000 0.865 0.446 1.000 
KCNA1-I chr12 5018715 5018806 0.269 1.000 0.904 0.529 1.000 
KCNA1-J chr12 5018984 5019092 0.233 1.000 0.906 0.536 1.000 
OPRK1-K chr8 54164081 54164162 0.355 1.000 0.894 0.506 1.000 
OPRK1-L chr8 54164296 54164392 0.358 0.933 0.930 0.592 0.992 
PRKAR1B-M chr7 751830 751963 0.479 1.000 0.964 0.750 1.000 
SLC8A1-N chr2 40678618 40678692 0.475 1.000 0.896 0.511 1.000 
SYN3-O chr22 33453893 33453995 0.372 1.000 0.923 0.584 1.000 
SYN3-P chr22 33454209 33454325 0.342 0.978 0.925 0.587 0.997 
SYN3-Q chr22 33454444 33454505 0.185 0.956 0.834 0.384 0.994 
SCTR-R chr2 120281719 120281813 0.202 0.978 0.923 0.579 0.997 
GRIA4-S chr11 105481283 105481406 0.347 1.000 0.957 0.714 1.000 
VIPR2-T chr7 158936508 158936632 0.320 1.000 0.959 0.726 1.000 
VIPR2-U chr7 158936632 158936739 0.148 0.978 0.978 0.830 0.998 
VIPR2-V chr7 158937494 158937610 0.343 1.000 0.947 0.672 1.000 
VIPR2-W chr7 158937969 158938060 0.440 1.000 0.961 0.738 1.000 
Supporting Information Table 5: 
 
A) CRC pathways most affected by aberrant methylations 
 






Hit Count in 
Query List 
Hit Count in 
Genome 
Wnt signaling pathway PantherDB 1,67E-10 2,13E-07 1,46E-07 1,13E-06 35 305 
Neuronal System BioSystems: REACTOME 2,28E-10 2,92E-07 1,46E-07 1,13E-06 34 293 
Cadherin signaling pathway PantherDB 5,74E-10 7,33E-07 2,44E-07 1,89E-06 24 159 
Transmission across Chemical Synapses BioSystems: REACTOME 2,97E-09 3,79E-06 9,48E-07 7,33E-06 26 200 
Neuroactive ligand-receptor interaction BioSystems: KEGG 4,46E-08 5,69E-05 1,14E-05 8,80E-05 29 275 
Neurotransmitter Release Cycle BioSystems: REACTOME 2,53E-07 3,23E-04 5,38E-05 4,16E-04 10 37 
GABAergic synapse BioSystems: KEGG 1,63E-06 2,09E-03 2,98E-04 2,30E-03 14 90 
Ensemble of genes encoding core 
extracellular matrix including ECM 
glycoproteins, collagens and 
proteoglycans 
MSigDB C2 BIOCARTA (v5.1) 1,87E-06 2,39E-03 2,99E-04 2,31E-03 26 275 
Calcium signaling pathway BioSystems: KEGG 2,82E-06 3,61E-03 4,01E-04 3,10E-03 20 181 
Cholinergic synapse BioSystems: KEGG 5,37E-06 6,86E-03 6,86E-04 5,30E-03 15 113 
Metabotropic glutamate receptor group 
III pathway 
PantherDB 8,01E-06 1,02E-02 9,30E-04 7,19E-03 11 64 
Ionotropic glutamate receptor pathway PantherDB 1,82E-05 2,33E-02 1,94E-03 1,50E-02 9 46 
Naعج dependent neurotransmitter 
transporters 
BioSystems: REACTOME 2,59E-05 3,31E-02 2,24E-03 1,73E-02 6 19 
GABA synthesis, release, reuptake and 
degradation 
BioSystems: REACTOME 2,59E-05 3,31E-02 2,24E-03 1,73E-02 6 19 
Ensemble of genes encoding extracellular 
matrix and extracellular matrix-
associated proteins  
MSigDB C2 BIOCARTA (v5.1) 2,75E-05 3,51E-02 2,24E-03 1,73E-02 59 1028 
Extracellular matrix organization BioSystems: REACTOME 2,80E-05 3,58E-02 2,24E-03 1,73E-02 23 264 
Glutamatergic synapse BioSystems: KEGG 3,31E-05 4,23E-02 2,40E-03 1,85E-02 14 116 
Cell adhesion molecules (CAMs) BioSystems: KEGG 3,38E-05 4,32E-02 2,40E-03 1,85E-02 16 147 
Cardiac Progenitor Differentiation BioSystems: WikiPathways 5,95E-05 7,60E-02 4,00E-03 3,09E-02 9 53 
Heart Development BioSystems: WikiPathways 1,51E-04 1,93E-01 9,19E-03 7,11E-02 8 47 
Insulin secretion BioSystems: KEGG 1,51E-04 1,93E-01 9,19E-03 7,11E-02 11 87 
GABA-B receptor II signaling PantherDB 1,65E-04 2,10E-01 9,56E-03 7,39E-02 7 36 
NCAM1 interactions BioSystems: REACTOME 1,97E-04 2,52E-01 1,10E-02 8,47E-02 7 37 
Morphine addiction BioSystems: KEGG 2,75E-04 3,51E-01 1,46E-02 1,13E-01 11 93 
Nicotine addiction BioSystems: KEGG 3,28E-04 4,19E-01 1,67E-02 1,29E-01 7 40 
Acetylcholine Neurotransmitter Release 
Cycle 
BioSystems: REACTOME 3,44E-04 4,39E-01 1,69E-02 1,31E-01 4 11 
Circadian entrainment BioSystems: KEGG 3,98E-04 5,08E-01 1,88E-02 1,46E-01 11 97 
Dopaminergic synapse BioSystems: KEGG 4,56E-04 5,83E-01 2,08E-02 1,61E-01 13 131 
Monoamine Transport BioSystems: WikiPathways 5,98E-04 7,64E-01 2,56E-02 1,98E-01 6 32 
Genes encoding collagen proteins MSigDB C2 BIOCARTA (v5.1) 6,00E-04 7,67E-01 2,56E-02 1,98E-01 7 44 
Genes encoding structural ECM 
glycoproteins 
MSigDB C2 BIOCARTA (v5.1) 9,41E-04 1,00E+00 3,88E-02 3,00E-01 16 196 
GABA synthesis BioSystems: REACTOME 1,17E-03 1,00E+00 4,48E-02 3,46E-01 2 2 
Transmembrane transport of small 
molecules 
BioSystems: REACTOME 1,18E-03 1,00E+00 4,48E-02 3,46E-01 32 537 
taurine and hypotaurine metabolic Pathway Ontology 1,19E-03 1,00E+00 4,48E-02 3,46E-01 3 7 
Maturity onset diabetes of the young BioSystems: KEGG 1,27E-03 1,00E+00 4,53E-02 3,50E-01 5 25 
GPCRs, Class C Metabotropic glutamate, 
pheromone 
BioSystems: WikiPathways 1,28E-03 1,00E+00 4,53E-02 3,50E-01 4 15 
Axon guidance BioSystems: REACTOME 1,36E-03 1,00E+00 4,70E-02 3,63E-01 19 262 
Collagen biosynthesis and modifying 
enzymes 















B) Adenoma pathways most affected by aberrant methylations 










Cadherin signaling pathway PantherDB 3,96E-26 7,88E-23 7,88E-23 6,45E-22 60 159 
Wnt signaling pathway PantherDB 1,44E-20 2,86E-17 1,43E-17 1,17E-16 77 305 
Neuroactive ligand-receptor 
interaction 
BioSystems: KEGG 3,73E-17 7,43E-14 2,48E-14 2,03E-13 67 275 
Neuronal System BioSystems: REACTOME 1,94E-12 3,87E-09 9,68E-10 7,91E-09 61 293 
Neural Crest Differentiation BioSystems: WikiPathways 6,20E-10 1,23E-06 2,47E-07 2,02E-06 29 101 
Extracellular matrix organization BioSystems: REACTOME 2,14E-09 4,26E-06 7,09E-07 5,80E-06 51 264 
Transmission across Chemical 
Synapses 
BioSystems: REACTOME 4,48E-09 8,91E-06 1,27E-06 1,04E-05 42 200 
Calcium signaling pathway BioSystems: KEGG 2,47E-08 4,91E-05 6,14E-06 5,02E-05 38 181 
GPCR ligand binding BioSystems: REACTOME 5,41E-07 1,08E-03 1,20E-04 9,78E-04 66 445 
Nicotine addiction BioSystems: KEGG 1,26E-06 2,51E-03 2,51E-04 2,05E-03 14 40 
Cardiac Progenitor Differentiation BioSystems: WikiPathways 2,12E-06 4,22E-03 3,84E-04 3,14E-03 16 53 
G protein signaling via Galphaq 
family 
Pathway Ontology 3,12E-06 6,22E-03 4,82E-04 3,94E-03 8 14 
G alpha (q) signalling events BioSystems: REACTOME 3,36E-06 6,68E-03 4,82E-04 3,94E-03 35 193 
Voltage gated Potassium channels BioSystems: REACTOME 3,39E-06 6,75E-03 4,82E-04 3,94E-03 14 43 
Glutamatergic synapse BioSystems: KEGG 3,70E-06 7,36E-03 4,91E-04 4,01E-03 25 116 
Class A/1 (Rhodopsin-like receptors) BioSystems: REACTOME 4,65E-06 9,25E-03 5,78E-04 4,73E-03 49 316 
Ensemble of genes encoding core 
extracellular matrix including ECM 
glycoproteins, collagens and 
proteoglycans 
MSigDB C2 BIOCARTA (v5.1) 6,27E-06 1,25E-02 7,34E-04 6,00E-03 44 275 
Metabotropic glutamate receptor 
group III pathway 
PantherDB 7,16E-06 1,43E-02 7,92E-04 6,47E-03 17 64 
Morphine addiction BioSystems: KEGG 1,02E-05 2,03E-02 1,07E-03 8,75E-03 21 93 
Maturity onset diabetes of the young BioSystems: KEGG 1,08E-05 2,16E-02 1,08E-03 8,81E-03 10 25 
Developmental Biology BioSystems: REACTOME 1,15E-05 2,29E-02 1,09E-03 8,90E-03 59 419 
Peptide ligand-binding receptors BioSystems: REACTOME 1,46E-05 2,90E-02 1,32E-03 1,08E-02 33 189 
Neurotransmitter Release Cycle BioSystems: REACTOME 1,78E-05 3,54E-02 1,54E-03 1,26E-02 12 37 
Circadian entrainment BioSystems: KEGG 2,03E-05 4,04E-02 1,68E-03 1,38E-02 21 97 
GABAergic synapse BioSystems: KEGG 2,12E-05 4,23E-02 1,69E-03 1,38E-02 20 90 
Ensemble of genes encoding 
extracellular matrix and extracellular 
MSigDB C2 BIOCARTA (v5.1) 2,28E-05 4,55E-02 1,75E-03 1,43E-02 118 1028 
matrix-associated proteins 
Cholinergic synapse BioSystems: KEGG 2,41E-05 4,79E-02 1,77E-03 1,45E-02 23 113 
Gastrin-CREB signalling pathway via 
PKC and MAPK 
BioSystems: REACTOME 3,44E-05 6,84E-02 2,44E-03 2,00E-02 35 214 
Ionotropic glutamate receptor 
pathway 
PantherDB 4,18E-05 8,33E-02 2,87E-03 2,35E-02 13 46 
Collagen formation BioSystems: REACTOME 4,39E-05 8,73E-02 2,91E-03 2,38E-02 19 87 
Heart Development BioSystems: WikiPathways 5,36E-05 1,07E-01 3,44E-03 2,82E-02 13 47 
Endogenous cannabinoid signaling PantherDB 5,54E-05 1,10E-01 3,45E-03 2,82E-02 9 24 
GABA-B receptor II signaling PantherDB 7,41E-05 1,48E-01 4,47E-03 3,66E-02 11 36 
NCAM1 interactions BioSystems: REACTOME 9,79E-05 1,95E-01 5,74E-03 4,69E-02 11 37 
Amoebiasis BioSystems: KEGG 1,24E-04 2,46E-01 7,03E-03 5,75E-02 21 109 
Peptide GPCRs BioSystems: WikiPathways 1,39E-04 2,77E-01 7,68E-03 6,28E-02 16 72 
Collagen biosynthesis and modifying 
enzymes 
BioSystems: REACTOME 1,43E-04 2,84E-01 7,68E-03 6,28E-02 15 65 
Neurotransmitter Receptor Binding 
And Downstream Transmission In 
The  Postsynaptic Cell 
BioSystems: REACTOME 1,70E-04 3,38E-01 8,74E-03 7,15E-02 25 144 
Integrin cell surface interactions BioSystems: REACTOME 1,71E-04 3,41E-01 8,74E-03 7,15E-02 15 66 
G alpha (i) signalling events BioSystems: REACTOME 3,02E-04 6,02E-01 1,50E-02 1,23E-01 35 238 
Potassium Channels BioSystems: REACTOME 3,52E-04 7,01E-01 1,71E-02 1,40E-01 19 101 
GABA synthesis, release, reuptake 
and degradation 
BioSystems: REACTOME 4,34E-04 8,64E-01 2,06E-02 1,68E-01 7 19 
Insulin secretion BioSystems: KEGG 4,48E-04 8,92E-01 2,06E-02 1,69E-01 17 87 
Retrograde endocannabinoid 
signaling 
BioSystems: KEGG 4,56E-04 9,08E-01 2,06E-02 1,69E-01 19 103 
Genes encoding collagen proteins MSigDB C2 BIOCARTA (v5.1) 5,24E-04 1,00E+00 2,31E-02 1,89E-01 11 44 
Synaptic Vesicle Pathway BioSystems: WikiPathways 5,38E-04 1,00E+00 2,31E-02 1,89E-01 12 51 
Endothelin signaling pathway PantherDB 5,48E-04 1,00E+00 2,31E-02 1,89E-01 15 73 
FOXA transcription factor networks BioSystems: Pathway Interaction 
Database 
5,56E-04 1,00E+00 2,31E-02 1,89E-01 3 3 
GPCRs, Class C Metabotropic 
glutamate, pheromone 
BioSystems: WikiPathways 6,82E-04 1,00E+00 2,77E-02 2,26E-01 6 15 
Regulation of beta-cell development BioSystems: REACTOME 8,49E-04 1,00E+00 3,38E-02 2,76E-01 9 33 
Regulation of gene expression in beta 
cells 
BioSystems: REACTOME 8,70E-04 1,00E+00 3,39E-02 2,78E-01 7 21 
Acetylcholine Neurotransmitter 
Release Cycle 
BioSystems: REACTOME 9,88E-04 1,00E+00 3,78E-02 3,09E-01 5 11 
Elastic fibre formation BioSystems: REACTOME 1,15E-03 1,00E+00 4,19E-02 3,43E-01 10 41 
Type II diabetes mellitus BioSystems: KEGG 1,15E-03 1,00E+00 4,19E-02 3,43E-01 11 48 
Transmembrane transport of small 
molecules 
BioSystems: REACTOME 1,18E-03 1,00E+00 4,19E-02 3,43E-01 63 537 
Heterotrimeric G-protein signaling 
pathway-Gq alpha and Go alpha 
mediated pathway 
PantherDB 1,18E-03 1,00E+00 4,19E-02 3,43E-01 19 111 
Cell adhesion molecules (CAMs) BioSystems: KEGG 1,36E-03 1,00E+00 4,74E-02 3,88E-01 23 147 
Unblocking of NMDA receptor, 
glutamate binding and activation 
BioSystems: REACTOME 1,47E-03 1,00E+00 4,95E-02 4,05E-01 6 17 
Focal Adhesion BioSystems: WikiPathways 1,47E-03 1,00E+00 4,95E-02 4,05E-01 27 184 
 
 
Supporting Information Table 6: 
 
A) genes belonging to the pathways most affected by methylation alterations in CRC 
 
SYMBOL ENSEMBL GENENAME 
ADAMTS2 ENSG00000087116 ADAM metallopeptidase with thrombospondin type 1 motif 2 
ADAMTS5 ENSG00000154736 ADAM metallopeptidase with thrombospondin type 1 motif 5 
ADCY1 ENSG00000164742 adenylate cyclase 1 (brain) 
ADCY8 ENSG00000155897 adenylate cyclase 8 (brain) 
ADRA1B ENSG00000170214 adrenoceptor alpha 1B 
AGRN ENSG00000188157 agrin 
APC2 ENSG00000115266 adenomatosis polyposis coli 2 
BMP2 ENSG00000125845 bone morphogenetic protein 2 
BRINP2 ENSG00000198797 BMP/retinoic acid inducible neural specific 2 
C1QL2 ENSG00000144119 complement component 1, q subcomponent-like 2 
C1QL3 ENSG00000165985 complement component 1, q subcomponent-like 3 
CACNA1A ENSG00000141837 calcium voltage-gated channel subunit alpha1 A 
CACNA1B ENSG00000148408 calcium voltage-gated channel subunit alpha1 B 
CACNA1E ENSG00000198216 calcium voltage-gated channel subunit alpha1 E 
CAMK2B ENSG00000058404 calcium/calmodulin-dependent protein kinase II beta 
CBLN1 ENSG00000102924 cerebellin 1 precursor 
CBLN2 ENSG00000141668 cerebellin 2 precursor 
CBLN4 ENSG00000054803 cerebellin 4 precursor 
CD34 ENSG00000174059 CD34 molecule 
CD8A ENSG00000153563 CD8a molecule 
CDH3 ENSG00000062038 cadherin 3 
CDH4 ENSG00000179242 cadherin 4 
CDH4 ENSG00000280641 cadherin 4 
CHAT ENSG00000070748 choline O-acetyltransferase 
CLEC14A ENSG00000176435 C-type lectin domain family 14 member A 
CNTN1 ENSG00000018236 contactin 1 
CNTNAP1 ENSG00000108797 contactin associated protein 1 
COL14A1 ENSG00000187955 collagen type XIV alpha 1 
COL15A1 ENSG00000204291 collagen type XV alpha 1 
COL23A1 ENSG00000050767 collagen type XXIII alpha 1 
COL24A1 ENSG00000171502 collagen type XXIV alpha 1 
COL26A1 ENSG00000160963 collagen type XXVI alpha 1 
COL4A1 ENSG00000187498 collagen type IV alpha 1 
COL4A2 ENSG00000134871 collagen type IV alpha 2 
CPLX1 ENSG00000168993 complexin 1 
CREB3L1 ENSG00000157613 cAMP responsive element binding protein 3-like 1 
CREB5 ENSG00000146592 cAMP responsive element binding protein 5 
CRHBP ENSG00000145708 corticotropin releasing hormone binding protein 
CRHR2 ENSG00000106113 corticotropin releasing hormone receptor 2 
CRISPLD1 ENSG00000121005 cysteine rich secretory protein LCCL domain containing 1 
CTBP2 ENSG00000175029 C-terminal binding protein 2 
DKK2 ENSG00000155011 dickkopf WNT signaling pathway inhibitor 2 
DRD5 ENSG00000169676 dopamine receptor D5 
EDNRB ENSG00000136160 endothelin receptor type B 
EMILIN3 ENSG00000183798 elastin microfibril interfacer 3 
EN2 ENSG00000164778 engrailed homeobox 2 
FBN1 ENSG00000166147 fibrillin 1 
FBN2 ENSG00000138829 fibrillin 2 
FGF12 ENSG00000114279 fibroblast growth factor 12 
FGF14 ENSG00000102466 fibroblast growth factor 14 
FGF5 ENSG00000138675 fibroblast growth factor 5 
FGF8 ENSG00000107831 fibroblast growth factor 8 
FNDC1 ENSG00000164694 fibronectin type III domain containing 1 
FREM3 ENSG00000183090 FRAS1 related extracellular matrix 3 
GABBR2 ENSG00000136928 gamma-aminobutyric acid type B receptor subunit 2 
GABRB1 ENSG00000163288 gamma-aminobutyric acid type A receptor beta1 subunit 
GAD1 ENSG00000128683 glutamate decarboxylase 1 
GAD2 ENSG00000136750 glutamate decarboxylase 2 
GDF6 ENSG00000156466 growth differentiation factor 6 
GDNF ENSG00000168621 glial cell derived neurotrophic factor 
GHSR ENSG00000121853 growth hormone secretagogue receptor 
GLRB ENSG00000109738 glycine receptor beta 
GNG7 ENSG00000176533 G protein subunit gamma 7 
GPC6 ENSG00000183098 glypican 6 
GPR83 ENSG00000123901 G protein-coupled receptor 83 
GRIA4 ENSG00000152578 glutamate ionotropic receptor AMPA type subunit 4 
GRIK3 ENSG00000163873 glutamate ionotropic receptor kainate type subunit 3 
GRIK5 ENSG00000105737 glutamate ionotropic receptor kainate type subunit 5 
GRIN2D ENSG00000105464 glutamate ionotropic receptor NMDA type subunit 2D 
GRIN3B ENSG00000116032 glutamate ionotropic receptor NMDA type subunit 3B 
GRM6 ENSG00000113262 glutamate receptor, metabotropic 6 
GRM7 ENSG00000196277 glutamate receptor, metabotropic 7 
HAPLN4 ENSG00000187664 hyaluronan and proteoglycan link protein 4 
HCN1 ENSG00000164588 hyperpolarization activated cyclic nucleotide gated potassium channel 1 
HPSE2 ENSG00000172987 heparanase 2 (inactive) 
HRH2 ENSG00000113749 histamine receptor H2 
HRNR ENSG00000197915 hornerin 
HTR1E ENSG00000168830 5-hydroxytryptamine receptor 1E 
ITGA4 ENSG00000115232 integrin subunit alpha 4 
ITGA8 ENSG00000077943 integrin subunit alpha 8 
JAM3 ENSG00000166086 junctional adhesion molecule 3 
KCNA1 ENSG00000111262 potassium voltage-gated channel subfamily A member 1 
KCNA3 ENSG00000177272 potassium voltage-gated channel subfamily A member 3 
KCNH1 ENSG00000143473 potassium voltage-gated channel subfamily H member 1 
KCNK7 ENSG00000173338 potassium two pore domain channel subfamily K member 7 
KCNQ2 ENSG00000075043 potassium voltage-gated channel subfamily Q member 2 
KCNQ2 ENSG00000281151 potassium voltage-gated channel subfamily Q member 2 
KCNQ5 ENSG00000185760 potassium voltage-gated channel subfamily Q member 5 
KY ENSG00000174611 kyphoscoliosis peptidase 
LAMA1 ENSG00000101680 laminin subunit alpha 1 
LHCGR ENSG00000138039 luteinizing hormone/choriogonadotropin receptor 
LRRC4 ENSG00000128594 leucine rich repeat containing 4 
LTBP4 ENSG00000090006 latent transforming growth factor beta binding protein 4 
MMP9 ENSG00000100985 matrix metallopeptidase 9 
NCAM1 ENSG00000149294 neural cell adhesion molecule 1 
NCAM2 ENSG00000154654 neural cell adhesion molecule 2 
NELL1 ENSG00000165973 neural EGFL like 1 
NGF ENSG00000134259 nerve growth factor 
NOS1 ENSG00000089250 nitric oxide synthase 1 
NPBWR1 ENSG00000183729 neuropeptides B/W receptor 1 
NPBWR2 ENSG00000277339 neuropeptides B/W receptor 2 
NPBWR2 ENSG00000125522 neuropeptides B/W receptor 2 
NPY2R ENSG00000185149 neuropeptide Y receptor Y2 
NPY4R ENSG00000204174 neuropeptide Y receptor Y4 
NRG1 ENSG00000157168 neuregulin 1 
NRG3 ENSG00000185737 neuregulin 3 
NRXN2 ENSG00000110076 neurexin 2 
NTSR1 ENSG00000101188 neurotensin receptor 1 (high affinity) 
OPRK1 ENSG00000082556 opioid receptor, kappa 1 
PCDHGA1 ENSG00000204956 protocadherin gamma subfamily A, 1 
PCDHGA10 ENSG00000253846 protocadherin gamma subfamily A, 10 
PCDHGA11 ENSG00000253873 protocadherin gamma subfamily A, 11 
PCDHGA12 ENSG00000253159 protocadherin gamma subfamily A, 12 
PCDHGA2 ENSG00000081853 protocadherin gamma subfamily A, 2 
PCDHGA3 ENSG00000254245 protocadherin gamma subfamily A, 3 
PCDHGA4 ENSG00000262576 protocadherin gamma subfamily A, 4 
PCDHGA5 ENSG00000253485 protocadherin gamma subfamily A, 5 
PCDHGA6 ENSG00000253731 protocadherin gamma subfamily A, 6 
PCDHGA7 ENSG00000253537 protocadherin gamma subfamily A, 7 
PCDHGA8 ENSG00000253767 protocadherin gamma subfamily A, 8 
PCDHGA9 ENSG00000261934 protocadherin gamma subfamily A, 9 
PCDHGB1 ENSG00000254221 protocadherin gamma subfamily B, 1 
PCDHGB2 ENSG00000253910 protocadherin gamma subfamily B, 2 
PCDHGB3 ENSG00000262209 protocadherin gamma subfamily B, 3 
PCDHGB4 ENSG00000253953 protocadherin gamma subfamily B, 4 
PCDHGB5 ENSG00000276547 protocadherin gamma subfamily B, 5 
PCDHGB6 ENSG00000253305 protocadherin gamma subfamily B, 6 
PCDHGB7 ENSG00000254122 protocadherin gamma subfamily B, 7 
PCDHGC3 ENSG00000240184 protocadherin gamma subfamily C, 3 
PCDHGC4 ENSG00000242419 protocadherin gamma subfamily C, 4 
PCDHGC5 ENSG00000240764 protocadherin gamma subfamily C, 5 
PDCD1 ENSG00000188389 programmed cell death 1 
PDCD1 ENSG00000276977 programmed cell death 1 
PDE1C ENSG00000154678 phosphodiesterase 1C 
PDGFD ENSG00000170962 platelet derived growth factor D 
PLCB1 ENSG00000182621 phospholipase C beta 1 
PPP2R5C ENSG00000078304 protein phosphatase 2 regulatory subunit B', gamma 
PRKAR1B ENSG00000188191 protein kinase cAMP-dependent type I regulatory subunit beta 
PRKCB ENSG00000166501 protein kinase C beta 
PTGFR ENSG00000122420 prostaglandin F receptor 
PTPRS ENSG00000105426 protein tyrosine phosphatase, receptor type S 
PXDN ENSG00000130508 peroxidasin 
RELN ENSG00000189056 reelin 
RSPO2 ENSG00000147655 R-spondin 2 
RSPO3 ENSG00000146374 R-spondin 3 
RYR2 ENSG00000198626 ryanodine receptor 2 
S1PR5 ENSG00000180739 sphingosine-1-phosphate receptor 5 
SCTR ENSG00000080293 secretin receptor 
SDC2 ENSG00000169439 syndecan 2 
SEMA6B ENSG00000167680 semaphorin 6B 
SFRP1 ENSG00000104332 secreted frizzled-related protein 1 
SFRP2 ENSG00000145423 secreted frizzled-related protein 2 
SHANK1 ENSG00000161681 SH3 and multiple ankyrin repeat domains 1 
SLC12A5 ENSG00000124140 solute carrier family 12 member 5 
SLC18A3 ENSG00000187714 solute carrier family 18 member A3 
SLC32A1 ENSG00000101438 solute carrier family 32 member 1 
SLC5A7 ENSG00000115665 solute carrier family 5 member 7 
SLC6A1 ENSG00000157103 solute carrier family 6 member 1 
SLC6A11 ENSG00000132164 solute carrier family 6 member 11 
SLC6A15 ENSG00000072041 solute carrier family 6 member 15 
SLC6A2 ENSG00000103546 solute carrier family 6 member 2 
SLC6A3 ENSG00000142319 solute carrier family 6 member 3 
SLC6A3 ENSG00000276996 solute carrier family 6 member 3 
SLC6A5 ENSG00000165970 solute carrier family 6 member 5 
SLC8A1 ENSG00000183023 solute carrier family 8 member A1 
SLIT2 ENSG00000145147 slit guidance ligand 2 
SLIT3 ENSG00000184347 slit guidance ligand 3 
SPOCK1 ENSG00000152377 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 
STX4 ENSG00000103496 syntaxin 4 
SYN3 ENSG00000185666 synapsin III 
T ENSG00000164458 T brachyury transcription factor 
TSPEAR ENSG00000175894 thrombospondin-type laminin G domain and EAR repeats 
VCAN ENSG00000038427 versican 
VEGFC ENSG00000150630 vascular endothelial growth factor C 
VIPR2 ENSG00000106018 vasoactive intestinal peptide receptor 2 





B) genes belonging to the pathways most affected by methylation alterations in adenoma 
SYMBOL ENSEMBL GENENAME 
ABLIM2 ENSG00000163995 actin binding LIM protein family member 2 
ACAN ENSG00000157766 aggrecan 
ACTA1 ENSG00000143632 actin, alpha 1, skeletal muscle 
ACTN2 ENSG00000077522 actinin alpha 2 
ACVR1C ENSG00000123612 activin A receptor type 1C 
ADAM30 ENSG00000134249 ADAM metallopeptidase domain 30 
ADAMTS10 ENSG00000142303 ADAM metallopeptidase with thrombospondin type 1 motif 10 
ADAMTS12 ENSG00000151388 ADAM metallopeptidase with thrombospondin type 1 motif 12 
ADAMTS12 ENSG00000281690 ADAM metallopeptidase with thrombospondin type 1 motif 12 
ADAMTS16 ENSG00000145536 ADAM metallopeptidase with thrombospondin type 1 motif 16 
ADAMTS2 ENSG00000087116 ADAM metallopeptidase with thrombospondin type 1 motif 2 
ADAMTS20 ENSG00000173157 ADAM metallopeptidase with thrombospondin type 1 motif 20 
ADAMTS5 ENSG00000154736 ADAM metallopeptidase with thrombospondin type 1 motif 5 
ADAMTSL3 ENSG00000156218 ADAMTS like 3 
ADCY8 ENSG00000155897 adenylate cyclase 8 (brain) 
ADCY9 ENSG00000162104 adenylate cyclase 9 
ADCYAP1 ENSG00000141433 adenylate cyclase activating polypeptide 1 (pituitary) 
ADCYAP1R1 ENSG00000078549 adenylate cyclase activating polypeptide 1 (pituitary) receptor type I 
ADRA1A ENSG00000120907 adrenoceptor alpha 1A 
ADRA1B ENSG00000170214 adrenoceptor alpha 1B 
AGTR1 ENSG00000144891 angiotensin II receptor type 1 
ANK1 ENSG00000029534 ankyrin 1 
APC2 ENSG00000115266 adenomatosis polyposis coli 2 
ARHGEF25 ENSG00000240771 Rho guanine nucleotide exchange factor 25 
ARTN ENSG00000117407 artemin 
ATP2A3 ENSG00000074370 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 
AVPR1A ENSG00000166148 arginine vasopressin receptor 1A 
AXIN2 ENSG00000168646 axin 2 
BCAN ENSG00000132692 brevican 
BMP2 ENSG00000125845 bone morphogenetic protein 2 
BMP4 ENSG00000125378 bone morphogenetic protein 4 
BMP7 ENSG00000101144 bone morphogenetic protein 7 
BRINP2 ENSG00000198797 BMP/retinoic acid inducible neural specific 2 
C1QL1 ENSG00000131094 complement component 1, q subcomponent-like 1 
C1QL2 ENSG00000144119 complement component 1, q subcomponent-like 2 
C1QL3 ENSG00000165985 complement component 1, q subcomponent-like 3 
C1QTNF8 ENSG00000184471 C1q and tumor necrosis factor related protein 8 
CACNA1A ENSG00000141837 calcium voltage-gated channel subunit alpha1 A 
CACNA1B ENSG00000148408 calcium voltage-gated channel subunit alpha1 B 
CACNA1E ENSG00000198216 calcium voltage-gated channel subunit alpha1 E 
CACNA1G ENSG00000006283 calcium voltage-gated channel subunit alpha1 G 
CACNA1H ENSG00000196557 calcium voltage-gated channel subunit alpha1 H 
CACNA1I ENSG00000100346 calcium voltage-gated channel subunit alpha1 I 
CACNB2 ENSG00000165995 calcium voltage-gated channel auxiliary subunit beta 2 
CACNG8 ENSG00000142408 calcium voltage-gated channel auxiliary subunit gamma 8 
CAPNS1 ENSG00000126247 calpain small subunit 1 
CASR ENSG00000036828 calcium sensing receptor 
CBLN1 ENSG00000102924 cerebellin 1 precursor 
CBLN2 ENSG00000141668 cerebellin 2 precursor 
CBLN4 ENSG00000054803 cerebellin 4 precursor 
CD38 ENSG00000004468 CD38 molecule 
CDH1 ENSG00000039068 cadherin 1 
CDH2 ENSG00000170558 cadherin 2 
CDH4 ENSG00000179242 cadherin 4 
CDH4 ENSG00000280641 cadherin 4 
CDH8 ENSG00000150394 cadherin 8 
CELSR1 ENSG00000075275 cadherin EGF LAG seven-pass G-type receptor 1 
CELSR3 ENSG00000008300 cadherin EGF LAG seven-pass G-type receptor 3 
CHAD ENSG00000136457 chondroadherin 
CHAT ENSG00000070748 choline O-acetyltransferase 
CHL1 ENSG00000134121 cell adhesion molecule L1 like 
CHRDL2 ENSG00000054938 chordin-like 2 
CHRM2 ENSG00000181072 cholinergic receptor muscarinic 2 
CHRNA4 ENSG00000101204 cholinergic receptor nicotinic alpha 4 subunit 
CLEC14A ENSG00000176435 C-type lectin domain family 14 member A 
CNTN1 ENSG00000018236 contactin 1 
CNTNAP1 ENSG00000108797 contactin associated protein 1 
COL20A1 ENSG00000101203 collagen type XX alpha 1 
COL21A1 ENSG00000124749 collagen type XXI alpha 1 
COL23A1 ENSG00000050767 collagen type XXIII alpha 1 
COL25A1 ENSG00000188517 collagen type XXV alpha 1 
COL26A1 ENSG00000160963 collagen type XXVI alpha 1 
COL2A1 ENSG00000139219 collagen type II alpha 1 
COL4A1 ENSG00000187498 collagen type IV alpha 1 
COL4A2 ENSG00000134871 collagen type IV alpha 2 
COL5A1 ENSG00000130635 collagen type V alpha 1 
COL5A3 ENSG00000080573 collagen type V alpha 3 
COL9A1 ENSG00000112280 collagen type IX alpha 1 
CPLX1 ENSG00000168993 complexin 1 
CREB3L1 ENSG00000157613 cAMP responsive element binding protein 3-like 1 
CREB5 ENSG00000146592 cAMP responsive element binding protein 5 
CRHBP ENSG00000145708 corticotropin releasing hormone binding protein 
CRHR2 ENSG00000106113 corticotropin releasing hormone receptor 2 
CRISPLD1 ENSG00000121005 cysteine rich secretory protein LCCL domain containing 1 
CRMP1 ENSG00000072832 collapsin response mediator protein 1 
CSNK1G2 ENSG00000133275 casein kinase 1 gamma 2 
CST3 ENSG00000101439 cystatin C 
CTNNA2 ENSG00000066032 catenin alpha 2 
CTSL ENSG00000135047 cathepsin L 
CXCL2 ENSG00000081041 C-X-C motif chemokine ligand 2 
DGKG ENSG00000058866 diacylglycerol kinase gamma 
DGKI ENSG00000157680 diacylglycerol kinase iota 
DGKQ ENSG00000145214 diacylglycerol kinase theta 
DKK2 ENSG00000155011 dickkopf WNT signaling pathway inhibitor 2 
DLX5 ENSG00000105880 distal-less homeobox 5 
DNM1 ENSG00000106976 dynamin 1 
DOCK1 ENSG00000150760 dedicator of cytokinesis 1 
EBF1 ENSG00000164330 early B-cell factor 1 
EDN3 ENSG00000124205 endothelin 3 
EDNRB ENSG00000136160 endothelin receptor type B 
EFEMP1 ENSG00000115380 EGF containing fibulin-like extracellular matrix protein 1 
EGFLAM ENSG00000164318 EGF like, fibronectin type III and laminin G domains 
EGLN2 ENSG00000269858 egl-9 family hypoxia-inducible factor 2 
EGLN3 ENSG00000129521 egl-9 family hypoxia-inducible factor 3 
ELFN1 ENSG00000225968 extracellular leucine-rich repeat and fibronectin type III domain containing 1 
EMILIN1 ENSG00000138080 elastin microfibril interfacer 1 
EMILIN3 ENSG00000183798 elastin microfibril interfacer 3 
EN1 ENSG00000163064 engrailed homeobox 1 
EN2 ENSG00000164778 engrailed homeobox 2 
ERBB2 ENSG00000141736 erb-b2 receptor tyrosine kinase 2 
F2RL1 ENSG00000164251 F2R like trypsin receptor 1 
F7 ENSG00000057593 coagulation factor VII 
FAT1 ENSG00000083857 FAT atypical cadherin 1 
FBLN7 ENSG00000144152 fibulin 7 
FBN1 ENSG00000166147 fibrillin 1 
FBN2 ENSG00000138829 fibrillin 2 
FFAR1 ENSG00000126266 free fatty acid receptor 1 
FGF12 ENSG00000114279 fibroblast growth factor 12 
FGF14 ENSG00000102466 fibroblast growth factor 14 
FGF17 ENSG00000158815 fibroblast growth factor 17 
FGF3 ENSG00000186895 fibroblast growth factor 3 
FGF5 ENSG00000138675 fibroblast growth factor 5 
FGF8 ENSG00000107831 fibroblast growth factor 8 
FNDC1 ENSG00000164694 fibronectin type III domain containing 1 
FOXA2 ENSG00000125798 forkhead box A2 
FOXA3 ENSG00000170608 forkhead box A3 
FREM3 ENSG00000183090 FRAS1 related extracellular matrix 3 
FZD10 ENSG00000111432 frizzled class receptor 10 
FZD2 ENSG00000180340 frizzled class receptor 2 
GABBR1 ENSG00000204681 gamma-aminobutyric acid type B receptor subunit 1 
GABBR1 ENSG00000206466 gamma-aminobutyric acid type B receptor subunit 1 
GABBR1 ENSG00000232632 gamma-aminobutyric acid type B receptor subunit 1 
GABBR1 ENSG00000237051 gamma-aminobutyric acid type B receptor subunit 1 
GABBR1 ENSG00000232569 gamma-aminobutyric acid type B receptor subunit 1 
GABBR1 ENSG00000237112 gamma-aminobutyric acid type B receptor subunit 1 
GABBR1 ENSG00000206511 gamma-aminobutyric acid type B receptor subunit 1 
GABRA2 ENSG00000151834 gamma-aminobutyric acid type A receptor alpha2 subunit 
GABRA5 ENSG00000186297 gamma-aminobutyric acid type A receptor alpha5 subunit 
GABRB3 ENSG00000166206 gamma-aminobutyric acid type A receptor beta3 subunit 
GABRG3 ENSG00000182256 gamma-aminobutyric acid type A receptor gamma3 subunit 
GAD1 ENSG00000128683 glutamate decarboxylase 1 
GAD2 ENSG00000136750 glutamate decarboxylase 2 
GALR1 ENSG00000166573 galanin receptor 1 
GATA4 ENSG00000136574 GATA binding protein 4 
GDF1 ENSG00000130283 growth differentiation factor 1 
GDF1 ENSG00000223802 growth differentiation factor 1 
GDF6 ENSG00000156466 growth differentiation factor 6 
GDNF ENSG00000168621 glial cell derived neurotrophic factor 
GFRA1 ENSG00000151892 GDNF family receptor alpha 1 
GFRA4 ENSG00000125861 GDNF family receptor alpha 4 
GHSR ENSG00000121853 growth hormone secretagogue receptor 
GJD2 ENSG00000159248 gap junction protein delta 2 
GLRA3 ENSG00000145451 glycine receptor alpha 3 
GLRB ENSG00000109738 glycine receptor beta 
GNA11 ENSG00000088256 G protein subunit alpha 11 
GNAI1 ENSG00000127955 G protein subunit alpha i1 
GNAL ENSG00000141404 G protein subunit alpha L 
GNAO1 ENSG00000087258 G protein subunit alpha o1 
GNAS ENSG00000087460 GNAS complex locus 
GNB4 ENSG00000114450 G protein subunit beta 4 
GNG7 ENSG00000176533 G protein subunit gamma 7 
GPC6 ENSG00000183098 glypican 6 
GPR39 ENSG00000183840 G protein-coupled receptor 39 
GRIA2 ENSG00000120251 glutamate ionotropic receptor AMPA type subunit 2 
GRIA4 ENSG00000152578 glutamate ionotropic receptor AMPA type subunit 4 
GRID1 ENSG00000182771 glutamate ionotropic receptor delta type subunit 1 
GRID2 ENSG00000152208 glutamate ionotropic receptor delta type subunit 2 
GRIK1 ENSG00000171189 glutamate ionotropic receptor kainate type subunit 1 
GRIK2 ENSG00000164418 glutamate ionotropic receptor kainate type subunit 2 
GRIK3 ENSG00000163873 glutamate ionotropic receptor kainate type subunit 3 
GRIN2A ENSG00000183454 glutamate ionotropic receptor NMDA type subunit 2A 
GRIN2D ENSG00000105464 glutamate ionotropic receptor NMDA type subunit 2D 
GRIN3B ENSG00000116032 glutamate ionotropic receptor NMDA type subunit 3B 
GRM1 ENSG00000152822 glutamate receptor, metabotropic 1 
GRM6 ENSG00000113262 glutamate receptor, metabotropic 6 
GRM7 ENSG00000196277 glutamate receptor, metabotropic 7 
GRP ENSG00000134443 gastrin releasing peptide 
GUCY1B3 ENSG00000061918 guanylate cyclase 1, soluble, beta 3 
HAND1 ENSG00000113196 heart and neural crest derivatives expressed 1 
HAPLN4 ENSG00000187664 hyaluronan and proteoglycan link protein 4 
HCN2 ENSG00000099822 hyperpolarization activated cyclic nucleotide gated potassium channel 2 
HCRTR2 ENSG00000137252 hypocretin receptor 2 
HEBP1 ENSG00000013583 heme binding protein 1 
HPSE2 ENSG00000172987 heparanase 2 (inactive) 
HRH2 ENSG00000113749 histamine receptor H2 
HTR1A ENSG00000178394 5-hydroxytryptamine receptor 1A 
HTR1E ENSG00000168830 5-hydroxytryptamine receptor 1E 
HTR5A ENSG00000157219 5-hydroxytryptamine receptor 5A 
IRX4 ENSG00000113430 iroquois homeobox 4 
ISL1 ENSG00000016082 ISL LIM homeobox 1 
ITGA4 ENSG00000115232 integrin subunit alpha 4 
ITGA8 ENSG00000077943 integrin subunit alpha 8 
ITGAD ENSG00000156886 integrin subunit alpha D 
ITGAM ENSG00000169896 integrin subunit alpha M 
ITGAX ENSG00000140678 integrin subunit alpha X 
JAM2 ENSG00000154721 junctional adhesion molecule 2 
JAM3 ENSG00000166086 junctional adhesion molecule 3 
KAZALD1 ENSG00000107821 Kazal type serine peptidase inhibitor domain 1 
KCNA1 ENSG00000111262 potassium voltage-gated channel subfamily A member 1 
KCNA3 ENSG00000177272 potassium voltage-gated channel subfamily A member 3 
KCNA4 ENSG00000182255 potassium voltage-gated channel subfamily A member 4 
KCNA5 ENSG00000130037 potassium voltage-gated channel subfamily A member 5 
KCNA6 ENSG00000130035 potassium voltage-gated channel subfamily A member 6 
KCNA6 ENSG00000151079 potassium voltage-gated channel subfamily A member 6 
KCNAB1 ENSG00000169282 
potassium voltage-gated channel subfamily A member regulatory beta 
subunit 1 
KCNAB2 ENSG00000069424 potassium voltage-gated channel subfamily A regulatory beta subunit 2 
KCNAB3 ENSG00000170049 potassium voltage-gated channel subfamily A regulatory beta subunit 3 
KCNC2 ENSG00000166006 potassium voltage-gated channel subfamily C member 2 
KCNH5 ENSG00000140015 potassium voltage-gated channel subfamily H member 5 
KCNK1 ENSG00000135750 potassium two pore domain channel subfamily K member 1 
KCNN1 ENSG00000105642 potassium calcium-activated channel subfamily N member 1 
KCNQ4 ENSG00000117013 potassium voltage-gated channel subfamily Q member 4 
KCNQ5 ENSG00000185760 potassium voltage-gated channel subfamily Q member 5 
KCNS1 ENSG00000124134 potassium voltage-gated channel modifier subfamily S member 1 
KCNV1 ENSG00000164794 potassium voltage-gated channel modifier subfamily V member 1 
KDR ENSG00000128052 kinase insert domain receptor 
KITLG ENSG00000049130 KIT ligand 
KY ENSG00000174611 kyphoscoliosis peptidase 
LAMA1 ENSG00000101680 laminin subunit alpha 1 
LAMB1 ENSG00000091136 laminin subunit beta 1 
LAMB3 ENSG00000196878 laminin subunit beta 3 
LEFTY2 ENSG00000143768 left-right determination factor 2 
LEP ENSG00000174697 leptin 
LEPR ENSG00000116678 leptin receptor 
LHCGR ENSG00000138039 luteinizing hormone/choriogonadotropin receptor 
LHX5 ENSG00000089116 LIM homeobox 5 
LIN28B ENSG00000187772 lin-28 homolog B 
LPAR1 ENSG00000198121 lysophosphatidic acid receptor 1 
LTBP3 ENSG00000168056 latent transforming growth factor beta binding protein 3 
LTBP4 ENSG00000090006 latent transforming growth factor beta binding protein 4 
MADCAM1 ENSG00000099866 mucosal vascular addressin cell adhesion molecule 1 
MATN3 ENSG00000132031 matrilin 3 
MBP ENSG00000197971 myelin basic protein 
MCHR2 ENSG00000152034 melanin concentrating hormone receptor 2 
MED16 ENSG00000175221 mediator complex subunit 16 
MED16 ENSG00000282092 mediator complex subunit 16 
MED30 ENSG00000164758 mediator complex subunit 30 
MLNR ENSG00000102539 motilin receptor 
MMP16 ENSG00000156103 matrix metallopeptidase 16 
MMP9 ENSG00000100985 matrix metallopeptidase 9 
MNX1 ENSG00000130675 motor neuron and pancreas homeobox 1 
MSX1 ENSG00000163132 msh homeobox 1 
MSX2 ENSG00000120149 msh homeobox 2 
MTNR1B ENSG00000134640 melatonin receptor 1B 
MYF5 ENSG00000111049 myogenic factor 5 
MYF6 ENSG00000111046 myogenic factor 6 
MYH14 ENSG00000105357 myosin, heavy chain 14, non-muscle 
MYH9 ENSG00000100345 myosin, heavy chain 9, non-muscle 
MYOD1 ENSG00000129152 myogenic differentiation 1 
NCOR2 ENSG00000196498 nuclear receptor corepressor 2 
NEFL ENSG00000277586 neurofilament, light polypeptide 
NELL1 ENSG00000165973 neural EGFL like 1 
NEUROD1 ENSG00000162992 neuronal differentiation 1 
NKD1 ENSG00000140807 naked cuticle homolog 1 (Drosophila) 
NKX2-2 ENSG00000125820 NK2 homeobox 2 
NKX2-5 ENSG00000183072 NK2 homeobox 5 
NMBR ENSG00000135577 neuromedin B receptor 
NOS1 ENSG00000089250 nitric oxide synthase 1 
NOS3 ENSG00000164867 nitric oxide synthase 3 
NOV ENSG00000136999 nephroblastoma overexpressed 
NPBWR1 ENSG00000183729 neuropeptides B/W receptor 1 
NPFFR2 ENSG00000056291 neuropeptide FF receptor 2 
NPY ENSG00000122585 neuropeptide Y 
NPY2R ENSG00000185149 neuropeptide Y receptor Y2 
NPY4R ENSG00000204174 neuropeptide Y receptor Y4 
NR2F2 ENSG00000185551 nuclear receptor subfamily 2 group F member 2 
NR5A2 ENSG00000116833 nuclear receptor subfamily 5 group A member 2 
NRG1 ENSG00000157168 neuregulin 1 
NRG3 ENSG00000185737 neuregulin 3 
NRXN1 ENSG00000179915 neurexin 1 
NTF3 ENSG00000185652 neurotrophin 3 
NTSR2 ENSG00000169006 neurotensin receptor 2 
OLIG2 ENSG00000205927 oligodendrocyte lineage transcription factor 2 
OLIG3 ENSG00000177468 oligodendrocyte transcription factor 3 
ONECUT1 ENSG00000169856 one cut homeobox 1 
OPRK1 ENSG00000082556 opioid receptor, kappa 1 
OPRM1 ENSG00000112038 opioid receptor, mu 1 
ORAI3 ENSG00000175938 ORAI calcium release-activated calcium modulator 3 
P2RX2 ENSG00000187848 purinergic receptor P2X 2 
P2RY6 ENSG00000171631 pyrimidinergic receptor P2Y6 
P4HA3 ENSG00000149380 prolyl 4-hydroxylase subunit alpha 3 
P4HB ENSG00000185624 prolyl 4-hydroxylase subunit beta 
PAX3 ENSG00000135903 paired box 3 
PAX6 ENSG00000007372 paired box 6 
PAX7 ENSG00000009709 paired box 7 
PCDH1 ENSG00000156453 protocadherin 1 
PCDH10 ENSG00000138650 protocadherin 10 
PCDH8 ENSG00000136099 protocadherin 8 
PCDH9 ENSG00000184226 protocadherin 9 
PCDHA1 ENSG00000204970 protocadherin alpha 1 
PCDHA10 ENSG00000250120 protocadherin alpha 10 
PCDHA11 ENSG00000249158 protocadherin alpha 11 
PCDHA12 ENSG00000251664 protocadherin alpha 12 
PCDHA13 ENSG00000239389 protocadherin alpha 13 
PCDHA2 ENSG00000204969 protocadherin alpha 2 
PCDHA3 ENSG00000255408 protocadherin alpha 3 
PCDHA4 ENSG00000204967 protocadherin alpha 4 
PCDHA5 ENSG00000204965 protocadherin alpha 5 
PCDHA6 ENSG00000081842 protocadherin alpha 6 
PCDHA7 ENSG00000204963 protocadherin alpha 7 
PCDHA8 ENSG00000204962 protocadherin alpha 8 
PCDHA9 ENSG00000204961 protocadherin alpha 9 
PCDHB12 ENSG00000120328 protocadherin beta 12 
PCDHB13 ENSG00000187372 protocadherin beta 13 
PCDHB15 ENSG00000113248 protocadherin beta 15 
PCDHB16 ENSG00000272674 protocadherin beta 16 
PCDHB4 ENSG00000081818 protocadherin beta 4 
PCDHB5 ENSG00000113209 protocadherin beta 5 
PCDHB6 ENSG00000113211 protocadherin beta 6 
PCDHGA1 ENSG00000204956 protocadherin gamma subfamily A, 1 
PCDHGA10 ENSG00000253846 protocadherin gamma subfamily A, 10 
PCDHGA11 ENSG00000253873 protocadherin gamma subfamily A, 11 
PCDHGA12 ENSG00000253159 protocadherin gamma subfamily A, 12 
PCDHGA2 ENSG00000081853 protocadherin gamma subfamily A, 2 
PCDHGA3 ENSG00000254245 protocadherin gamma subfamily A, 3 
PCDHGA4 ENSG00000262576 protocadherin gamma subfamily A, 4 
PCDHGA5 ENSG00000253485 protocadherin gamma subfamily A, 5 
PCDHGA6 ENSG00000253731 protocadherin gamma subfamily A, 6 
PCDHGA7 ENSG00000253537 protocadherin gamma subfamily A, 7 
PCDHGA8 ENSG00000253767 protocadherin gamma subfamily A, 8 
PCDHGA9 ENSG00000261934 protocadherin gamma subfamily A, 9 
PCDHGB1 ENSG00000254221 protocadherin gamma subfamily B, 1 
PCDHGB2 ENSG00000253910 protocadherin gamma subfamily B, 2 
PCDHGB3 ENSG00000262209 protocadherin gamma subfamily B, 3 
PCDHGB4 ENSG00000253953 protocadherin gamma subfamily B, 4 
PCDHGB5 ENSG00000276547 protocadherin gamma subfamily B, 5 
PCDHGB6 ENSG00000253305 protocadherin gamma subfamily B, 6 
PCDHGB7 ENSG00000254122 protocadherin gamma subfamily B, 7 
PCDHGC3 ENSG00000240184 protocadherin gamma subfamily C, 3 
PCDHGC4 ENSG00000242419 protocadherin gamma subfamily C, 4 
PCDHGC5 ENSG00000240764 protocadherin gamma subfamily C, 5 
PCSK5 ENSG00000099139 proprotein convertase subtilisin/kexin type 5 
PDE11A ENSG00000128655 phosphodiesterase 11A 
PDE4C ENSG00000105650 phosphodiesterase 4C 
PDE4D ENSG00000113448 phosphodiesterase 4D 
PDE8B ENSG00000113231 phosphodiesterase 8B 
PDGFD ENSG00000170962 platelet derived growth factor D 
PDX1 ENSG00000139515 pancreatic and duodenal homeobox 1 
PENK ENSG00000181195 proenkephalin 
PHOX2B ENSG00000109132 paired like homeobox 2b 
PIK3CD ENSG00000171608 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta 
PIK3R2 ENSG00000105647 phosphoinositide-3-kinase regulatory subunit 2 
PIK3R5 ENSG00000141506 phosphoinositide-3-kinase regulatory subunit 5 
PIP5K1C ENSG00000186111 phosphatidylinositol-4-phosphate 5-kinase, type I, gamma 
PLCB1 ENSG00000182621 phospholipase C beta 1 
PLD1 ENSG00000075651 phospholipase D1 
PLEC ENSG00000178209 plectin 
PLOD2 ENSG00000152952 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 
PLXDC2 ENSG00000120594 plexin domain containing 2 
PMP22 ENSG00000109099 peripheral myelin protein 22 
PPP2R5C ENSG00000078304 protein phosphatase 2 regulatory subunit B', gamma 
PRKAR1B ENSG00000188191 protein kinase cAMP-dependent type I regulatory subunit beta 
PRKCB ENSG00000166501 protein kinase C beta 
PRKCZ ENSG00000067606 protein kinase C zeta 
PRLHR ENSG00000119973 prolactin releasing hormone receptor 
PROKR2 ENSG00000101292 prokineticin receptor 2 
PRSS3 ENSG00000010438 protease, serine 3 
PTGFR ENSG00000122420 prostaglandin F receptor 
PTH2R ENSG00000144407 parathyroid hormone 2 receptor 
PXDNL ENSG00000147485 peroxidasin like 
PYGO1 ENSG00000171016 pygopus family PHD finger 1 
QRFPR ENSG00000186867 pyroglutamylated RFamide peptide receptor 
RASGRF1 ENSG00000058335 Ras protein specific guanine nucleotide releasing factor 1 
ROBO1 ENSG00000169855 roundabout guidance receptor 1 
ROR2 ENSG00000169071 receptor tyrosine kinase-like orphan receptor 2 
RSPO2 ENSG00000147655 R-spondin 2 
RSPO3 ENSG00000146374 R-spondin 3 
RXFP3 ENSG00000277069 relaxin/insulin-like family peptide receptor 3 
RXFP3 ENSG00000182631 relaxin/insulin-like family peptide receptor 3 
RYR3 ENSG00000198838 ryanodine receptor 3 
S1PR1 ENSG00000170989 sphingosine-1-phosphate receptor 1 
S1PR3 ENSG00000213694 sphingosine-1-phosphate receptor 3 
SCN8A ENSG00000196876 sodium voltage-gated channel alpha subunit 8 
SCTR ENSG00000080293 secretin receptor 
SDC2 ENSG00000169439 syndecan 2 
SEMA3C ENSG00000075223 semaphorin 3C 
SEMA6B ENSG00000167680 semaphorin 6B 
SERPINB9 ENSG00000170542 serpin peptidase inhibitor, clade B (ovalbumin), member 9 
SFRP1 ENSG00000104332 secreted frizzled-related protein 1 
SFRP2 ENSG00000145423 secreted frizzled-related protein 2 
SHANK1 ENSG00000161681 SH3 and multiple ankyrin repeat domains 1 
SHANK2 ENSG00000162105 SH3 and multiple ankyrin repeat domains 2 
SLC12A5 ENSG00000124140 solute carrier family 12 member 5 
SLC17A6 ENSG00000091664 solute carrier family 17 member 6 
SLC18A3 ENSG00000187714 solute carrier family 18 member A3 
SLC2A2 ENSG00000163581 solute carrier family 2 member 2 
SLC32A1 ENSG00000101438 solute carrier family 32 member 1 
SLC5A7 ENSG00000115665 solute carrier family 5 member 7 
SLC6A1 ENSG00000157103 solute carrier family 6 member 1 
SLC6A11 ENSG00000132164 solute carrier family 6 member 11 
SLC6A3 ENSG00000142319 solute carrier family 6 member 3 
SLC6A3 ENSG00000276996 solute carrier family 6 member 3 
SLC8A1 ENSG00000183023 solute carrier family 8 member A1 
SLC8A2 ENSG00000118160 solute carrier family 8 member A2 
SLIT2 ENSG00000145147 slit guidance ligand 2 
SLIT3 ENSG00000184347 slit guidance ligand 3 
SNAI2 ENSG00000019549 snail family zinc finger 2 
SNAP25 ENSG00000132639 synaptosome associated protein 25kDa 
SOX10 ENSG00000100146 SRY-box 10 
SOX17 ENSG00000164736 SRY-box 17 
SOX5 ENSG00000134532 SRY-box 5 
SPOCK1 ENSG00000152377 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 
SPOCK3 ENSG00000196104 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 3 
SST ENSG00000157005 somatostatin 
SSTR1 ENSG00000139874 somatostatin receptor 1 
SSTR2 ENSG00000180616 somatostatin receptor 2 
SSTR4 ENSG00000132671 somatostatin receptor 4 
STX2 ENSG00000111450 syntaxin 2 
SYN2 ENSG00000157152 synapsin II 
SYN3 ENSG00000185666 synapsin III 
TACR3 ENSG00000169836 tachykinin receptor 3 
TAS1R3 ENSG00000169962 taste 1 receptor member 3 
TBX20 ENSG00000164532 T-box 20 
TBX5 ENSG00000089225 T-box 5 
TCF4 ENSG00000196628 transcription factor 4 
TDGF1 ENSG00000241186 teratocarcinoma-derived growth factor 1 
TFAP2A ENSG00000137203 transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) 
TFAP2B ENSG00000008196 transcription factor AP-2 beta (activating enhancer binding protein 2 beta) 
TGFB2 ENSG00000092969 transforming growth factor beta 2 
TGFBI ENSG00000120708 transforming growth factor beta induced 
THBS4 ENSG00000113296 thrombospondin 4 
THRA ENSG00000126351 thyroid hormone receptor, alpha 
THY1 ENSG00000154096 Thy-1 cell surface antigen 
TIMP4 ENSG00000157150 TIMP metallopeptidase inhibitor 4 
TLL1 ENSG00000038295 tolloid like 1 
TLX2 ENSG00000115297 T-cell leukemia homeobox 2 
TNFSF11 ENSG00000120659 tumor necrosis factor superfamily member 11 
TNFSF9 ENSG00000125657 tumor necrosis factor superfamily member 9 
TNNC2 ENSG00000101470 troponin C2, fast skeletal type 
TNNI3 ENSG00000129991 troponin I3, cardiac type 
TNR ENSG00000116147 tenascin R 
TRH ENSG00000170893 thyrotropin releasing hormone 
TRPC4 ENSG00000133107 transient receptor potential cation channel subfamily C member 4 
TRPC6 ENSG00000137672 transient receptor potential cation channel subfamily C member 6 
TSPEAR ENSG00000175894 thrombospondin-type laminin G domain and EAR repeats 
TWIST1 ENSG00000122691 twist family bHLH transcription factor 1 
UNC5C ENSG00000182168 unc-5 netrin receptor C 
UNC5D ENSG00000156687 unc-5 netrin receptor D 
VCAN ENSG00000038427 versican 
VEGFC ENSG00000150630 vascular endothelial growth factor C 
VIPR2 ENSG00000106018 vasoactive intestinal peptide receptor 2 
WIF1 ENSG00000156076 WNT inhibitory factor 1 
WNT3 ENSG00000108379 wingless-type MMTV integration site family member 3 
WNT3 ENSG00000277626 wingless-type MMTV integration site family member 3 
WNT3 ENSG00000277641 wingless-type MMTV integration site family member 3 
WNT5B ENSG00000111186 wingless-type MMTV integration site family member 5B 
ZIC1 ENSG00000152977 Zic family member 1 
 
Supporting Information Table 7: Early biomarkers panel of 74 CpG islands putative genes regulators significantly altered in CRC and adenomas 
 Discovery set 
In silico validation set 
TCGA  
 














ADAMTS2 0,35 0,12 0,22 0,52 0,1 0,42 0,2 0.96 0.98 0.91 <10E-8 <10E-8 <10E-8 E 
ADAMTS5 0,49 0,25 0,24 0,55 0,21 0,33 0,09 0.97 0.95 0.92 <10E-8 <10E-8 <10E-8 E, ER 
ADCY8 0,49 0,29 0,2 0,6 0,35 0,25 0,05 0.98 0.98 0.89 <10E-8 <10E-8 <10E-8 P, C 
ADRA1B 0,33 0,14 0,18 0,48 0,15 0,33 0,15 0.97 0.95 0.94 4E-08 <10E-8 <10E-8 P, N 
CACNA1A 0,48 0,24 0,24 0,58 0,21 0,38 0,13 1 0.95 0.97 <10E-8 <10E-8 <10E-8 P, N 
CACNA1E 0,51 0,29 0,22 0,59 0,35 0,25 0,03 0.96 1 0.86 <10E-8 <10E-8 <10E-8 P 
CDH4 0,48 0,17 0,3 0,64 0,15 0,49 0,19 0.96 1 0.93 <10E-8 <10E-8 <10E-8 P 
COL23A1 0,34 0,13 0,2 0,51 0,12 0,39 0,19 0.96 1 0.89 <10E-8 <10E-8 <10E-8 P, ER, E 
COL4A1 0,45 0,19 0,26 0,59 0,19 0,4 0,14 0.98 0.95 0.94 <10E-8 <10E-8 <10E-8 E, ER 
CPLX1 0,47 0,28 0,19 0,59 0,28 0,32 0,13 0.98 1 0.96 <10E-8 <10E-8 <10E-8 C 
CREB3L1 0,5 0,33 0,18 0,61 0,18 0,43 0,25 0.92 0.91 0.79 <10E-8 <10E-8 <10E-8 N, ER 
CREB5 0,35 0,13 0,22 0,48 0,15 0,33 0,11 0.96 1 0.91 <10E-8 <10E-8 <10E-8 E, N 
CRHR2 0,37 0,15 0,23 0,49 0,13 0,36 0,13 0.96 1 0.91 <10E-8 <10E-8 <10E-8 P 
CRISPLD1 0,38 0,2 0,17 0,51 0,24 0,27 0,1 0.96 0.95 0.91 <10E-8 <10E-8 <10E-8 E 
DKK 2 0,45 0,15 0,3 0,54 0,19 0,35 0,05 0.97 1 0.91 <10E-8 <10E-8 <10E-8 E 
EDNRB 0,53 0,27 0,26 0,59 0,36 0,23 -0,03 0.9 0.89 0.85 <10E-8 <10E-8 <10E-8 P 
EN2 0,49 0,26 0,23 0,59 0,26 0,33 0,1 0.98 1 0.96 <10E-8 <10E-8 <10E-8 N 
FBN1 0,35 0,11 0,24 0,49 0,08 0,41 0,16 0.95 1 0.91 <10E-8 <10E-8 <10E-8 E, P 
FBN2 0,45 0,18 0,27 0,59 0,18 0,41 0,14 0.98 1 0.94 <10E-8 <10E-8 <10E-8 E 
FNDC1 0,43 0,16 0,27 0,52 0,13 0,39 0,12 0.96 1 0.9 <10E-8 <10E-8 <10E-8 N, E 
GAD2 0,47 0,21 0,26 0,55 0,24 0,31 0,05 0.99 1 0.95 <10E-8 <10E-8 <10E-8 P, C, GA 
GHSR 0,43 0,26 0,17 0,56 0,3 0,26 0,09 0.97 0.98 0.88 <10E-8 <10E-8 <10E-8 P 
GLRB 0,42 0,2 0,22 0,56 0,16 0,4 0,18 0.97 1 0.96 <10E-8 <10E-8 <10E-8 P 
GNG7 0,65 0,85 -0,2 0,6 0,89 -0,29 -0,09 0.94 0.95 0.86 <10E-8 <10E-8 <10E-8 E, P 
GRIA4 0,53 0,17 0,36 0,63 0,18 0,45 0,08 0.97 0.98 0.92 <10E-8 <10E-8 <10E-8 P, E 
GRIK3 0,49 0,27 0,21 0,58 0,29 0,29 0,08 0.97 0.98 0.94 <10E-8 <10E-8 <10E-8 P 
GRIN2D 0,42 0,17 0,25 0,58 0,17 0,42 0,16 0.98 0.98 0.94 3E-07 <10E-8 <10E-8 P 
GRIN2D_1 0,63 0,39 0,23 0,73 0,46 0,26 0,03 0.93 0.95 0.81 1E-06 <10E-8 <10E-8 P 
GRIN2D_2 0,53 0,34 0,19 0,63 0,33 0,31 0,11 0.97 1 0.9 <10E-8 <10E-8 <10E-8 P 
GRIN3B 0,64 0,83 -0,19 0,63 0,87 -0,24 -0,05 0.98 1 0.97 <10E-8 <10E-8 <10E-8 P 
GRM6 0,62 0,46 0,16 0,7 0,5 0,2 0,04 0.93 1 0.7 <10E-8 <10E-8 <10E-8 P, ER, GA 
GRM7 0,62 0,38 0,24 0,7 0,47 0,24 0 0.96 1 0.79 <10E-8 <10E-8 <10E-8 P 
HAPLN4 0,52 0,32 0,2 0,63 0,32 0,31 0,11 0.99 1 0.96 <10E-8 <10E-8 <10E-8 E 
HTR1E 0,46 0,22 0,25 0,59 0,27 0,32 0,08 0.96 1 0.88 <10E-8 <10E-8 <10E-8 P 
ITGA4 0,48 0,16 0,32 0,61 0,19 0,42 0,1 0.93 0.98 0.75 <10E-8 <10E-8 <10E-8 P, E 
ITGA8 0,4 0,16 0,24 0,53 0,17 0,36 0,12 0.98 1 0.93 <10E-8 <10E-8 <10E-8 P, ER 
JAM3 0,41 0,18 0,23 0,56 0,19 0,37 0,14 0.97 1 0.9 <10E-8 <10E-8 <10E-8 P, E 
KCNA1 0,46 0,25 0,21 0,55 0,23 0,32 0,11 0.96 0.98 0.9 <10E-8 <10E-8 <10E-8 P, ER, C 
KCNA3 0,55 0,35 0,2 0,67 0,39 0,29 0,08 0.98 0.98 0.91 <10E-8 <10E-8 <10E-8 P 
KCNQ5 0,44 0,15 0,29 0,57 0,14 0,44 0,15 0.98 1 0.94 <10E-8 <10E-8 <10E-8 P 
LAMA1 0,49 0,23 0,26 0,58 0,24 0,34 0,08 0.97 0.98 0.93 <10E-8 <10E-8 <10E-8 E 
LHCGR 0,56 0,37 0,19 0,66 0,39 0,28 0,09 0.89 0.98 0.77 <10E-8 <10E-8 <10E-8 P, EN 
MMP9 0,59 0,43 0,16 0,69 0,46 0,23 0,07 0.97 1 0.91 <10E-8 <10E-8 <10E-8 E, P, N 
NELL1 0,49 0,24 0,25 0,6 0,24 0,36 0,11 0.99 0.98 0.97 <10E-8 <10E-8 <10E-8 E, N 
NOS1 0,4 0,19 0,21 0,5 0,19 0,3 0,09 0.97 1 0.93 <10E-8 <10E-8 <10E-8 P, N, ER, C, CS, M 
NPBWR1 0,45 0,22 0,23 0,57 0,25 0,33 0,09 0.99 1 0.97 <10E-8 <10E-8 <10E-8 P 
NPY2R 0,38 0,16 0,22 0,47 0,16 0,32 0,09 0.97 0.95 0.91 <10E-8 <10E-8 <10E-8 P 
OPRK1 0,52 0,25 0,27 0,59 0,27 0,32 0,05 0.96 0.95 0.92 <10E-8 <10E-8 <10E-8 P 
PCDHG@ 0,64 0,38 0,26 0,74 0,44 0,31 0,05 0.98 0.98 0.96 <10E-8 <10E-8 <10E-8 P 
PCDHG@ 1 0,5 0,23 0,28 0,65 0,22 0,43 0,16 1 1 0.96 <10E-8 <10E-8 <10E-8 P 
PLCB1 0,44 0,18 0,26 0,57 0,16 0,41 0,14 0.99 0.98 0.96 <10E-8 <10E-8 <10E-8 E, N, C 
PRKAR1B 0,51 0,17 0,34 0,67 0,27 0,4 0,06 0.99 1 0.96 <10E-8 <10E-8 <10E-8 C 
PRKCB 0,25 0,06 0,19 0,38 0,05 0,32 0,13 0.96 1 0.89 <10E-8 <10E-8 <10E-8 P, E, N, C 
PTGFR 0,5 0,34 0,16 0,58 0,39 0,2 0,04 0.98 1 0.96 <10E-8 <10E-8 <10E-8 P, E 
RSPO2 0,44 0,18 0,26 0,56 0,18 0,38 0,12 0.99 0.98 0.95 <10E-8 <10E-8 <10E-8 E 
RSPO3 0,48 0,25 0,23 0,59 0,28 0,31 0,08 0.95 0.98 0.89 4E-06 <10E-8 <10E-8 E 
SCTR 0,5 0,26 0,24 0,64 0,24 0,4 0,17 0.91 0.95 0.78 <10E-8 <10E-8 <10E-8 P, CS 
SDC2 0,33 0,08 0,25 0,43 0,08 0,35 0,1 0.96 0.98 0.94 <10E-8 <10E-8 <10E-8 P, E, L, GA 
SFRP1 0,52 0,28 0,24 0,62 0,34 0,29 0,04 0.98 1 0.94 <10E-8 <10E-8 <10E-8 P, E, C 
SFRP2 0,41 0,19 0,22 0,54 0,16 0,38 0,16 0.96 1 0.93 <10E-8 <10E-8 <10E-8 E 
SHANK1 0,43 0,23 0,2 0,52 0,26 0,27 0,06 0.93 0.95 0.82 <10E-8 <10E-8 <10E-8 P, C, N 
SLC12A5 0,58 0,41 0,17 0,69 0,44 0,25 0,08 0.94 0.95 0.86 <10E-8 <10E-8 <10E-8 P 
SLC18A3 0,5 0,28 0,22 0,61 0,3 0,31 0,09 0.94 0.91 0.87 <10E-8 <10E-8 <10E-8 P, GA 
SLC32A1 0,48 0,28 0,19 0,57 0,3 0,27 0,08 0.99 0.98 0.95 <10E-8 <10E-8 <10E-8 P 
SLC5A7 0,44 0,25 0,18 0,56 0,25 0,31 0,12 0.98 1 0.92 <10E-8 <10E-8 <10E-8 P 
SLC6A1 0,49 0,31 0,18 0,57 0,31 0,25 0,07 0.97 1 0.92 <10E-8 <10E-8 <10E-8 P 
SLC6A11 0,55 0,39 0,16 0,65 0,42 0,22 0,06 0.97 0.98 0.88 <10E-8 <10E-8 <10E-8 P 
SLC6A3 0,43 0,23 0,2 0,58 0,25 0,33 0,13 0.98 1 0.92 <10E-8 <10E-8 <10E-8 P 
SLC8A1 0,56 0,25 0,3 0,69 0,31 0,38 0,08 0.99 0.98 0.96 3E-06 <10E-8 <10E-8 P, N 
SLIT3 0,49 0,19 0,3 0,6 0,19 0,4 0,1 0.96 1 0.92 <10E-8 <10E-8 <10E-8 E, M 
SPOCK1 0,39 0,17 0,23 0,53 0,17 0,37 0,14 0.98 1 0.95 <10E-8 <10E-8 <10E-8 E 
SYN3 0,4 0,19 0,22 0,51 0,17 0,34 0,13 0.92 1 0.8 <10E-8 <10E-8 <10E-8 C 
VCAN 0,36 0,11 0,25 0,49 0,1 0,39 0,15 0.93 1 0.86 <10E-8 <10E-8 <10E-8 E, L, GA 
VIPR2 0,48 0,23 0,26 0,64 0,23 0,41 0,15 0.99 1 0.97 <10E-8 <10E-8 <10E-8 P 
 
Extracellular = E 
Endoplasmic reticulum = ER 
Plasma membrane = P 
Nucleus = N 
Cytosol = C 
Golgi apparatus = GA 
Endosome = EN 
Cytoskeleton = CS 
Mitochondrion = M 
Lysosome = L 
 





AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.961 0.909 0.977 0.819 0.997 0.581 40.012 0.093 1 31 0.887 
95%_CI_lower_limit 0.943 0.874 0.882 - 0.982 0.467 5.762 0.066 - - - 
95%_CI_upper_limit 0.979 0.935 0.996 - 0.999 0.687 277.834 0.130 - - - 
             
ADAMTS5 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.989 0.953 0.977 0.866 0.997 0.729 41.942 0.048 1 16 0.930 
95%_CI_lower_limit 0.98 0.925 0.882 - 0.983 0.604 6.041 0.030 - - - 
95%_CI_upper_limit 0.998 0.971 0.996 - 0.999 0.826 291.192 0.077 - - - 
             
ADCY8 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.976 0.889 0.977 0.916 0.997 0.531 39.111 0.114 1 38 0.866 
95%_CI_lower_limit 0.962 0.851 0.882 - 0.982 0.423 5.632 0.084 - - - 
95%_CI_upper_limit 0.99 0.918 0.996 - 0.999 0.636 271.601 0.154 - - - 
             
ADRA1B 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.968 0.939 0.955 0.699 0.994 0.667 20.649 0.064 2 21 0.893 
95%_CI_lower_limit 0.951 0.908 0.849 - 0.978 0.544 5.330 0.042 - - - 
95%_CI_upper_limit 0.985 0.959 0.987 - 0.998 0.771 79.997 0.098 - - - 
             
CACNA1A 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.952 0.906 1.000 0.878 1.000 0.579 Inf 0.094 0 32 0.906 
95%_CI_lower_limit 0.93 0.871 0.920 - 0.988 0.467 NaN 0.067 - - - 
95%_CI_upper_limit 0.973 0.933 1.000 - 1.000 0.684 Inf 0.130 - - - 
             
CACNA1E 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.934 0.810 0.955 0.909 0.993 0.393 17.819 0.199 2 65 0.764 
95%_CI_lower_limit 0.908 0.765 0.849 - 0.974 0.305 4.596 0.159 - - - 
95%_CI_upper_limit 0.96 0.848 0.987 - 0.998 0.487 69.080 0.250 - - - 
             
CDH4 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.99 0.959 0.977 0.764 0.997 0.754 42.199 0.042 1 14 0.936 
95%_CI_lower_limit 0.981 0.932 0.882 - 0.983 0.629 6.078 0.025 - - - 
95%_CI_upper_limit 0.998 0.975 0.996 - 0.999 0.848 292.973 0.070 - - - 
             
COL23A1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.961 0.889 1.000 0.891 1.000 0.537 Inf 0.111 0 38 0.889 
95%_CI_lower_limit 0.943 0.851 0.920 - 0.988 0.429 NaN 0.082 - - - 
95%_CI_upper_limit 0.98 0.918 1.000 - 1.000 0.640 Inf 0.150 - - - 
             
COL4A1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 






Estimate 0.989 0.968 0.977 0.682 0.997 0.796 42.585 0.033 1 11 0.945 
95%_CI_lower_limit 0.98 0.943 0.882 - 0.983 0.671 6.134 0.018 - - - 
 95%_CI_upper_limit 0.997 0.982 0.996 - 0.999 0.882 295.644 0.059 - - - 
             
             
CPLX1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.984 0.965 1.000 0.724 1.000 0.786 Inf 0.035 0 12 0.965 
95%_CI_lower_limit 0.972 0.940 0.920 - 0.988 0.662 NaN 0.020 - - - 
95%_CI_upper_limit 0.996 0.980 1.000 - 1.000 0.873 Inf 0.061 - - - 
             
CREB3L1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.94 0.868 0.909 0.922 0.987 0.471 9.553 0.145 4 45 0.778 
95%_CI_lower_limit 0.915 0.828 0.788 - 0.966 0.368 3.749 0.109 - - - 
95%_CI_upper_limit 0.966 0.900 0.964 - 0.995 0.576 24.340 0.193 - - - 
             
CREB5 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.962 0.906 1.000 0.880 1.000 0.579 Inf 0.094 0 32 0.906 
95%_CI_lower_limit 0.943 0.871 0.920 - 0.988 0.467 NaN 0.067 - - - 
95%_CI_upper_limit 0.98 0.933 1.000 - 1.000 0.684 Inf 0.130 - - - 
             
CRHR2 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.956 0.909 1.000 0.881 1.000 0.587 Inf 0.091 0 31 0.909 
95%_CI_lower_limit 0.937 0.874 0.920 - 0.988 0.474 NaN 0.065 - - - 
95%_CI_upper_limit 0.976 0.935 1.000 - 1.000 0.691 Inf 0.127 - - - 
             
CRISPLD1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.961 0.912 0.955 0.849 0.994 0.583 20.070 0.092 2 30 0.867 
95%_CI_lower_limit 0.942 0.878 0.849 - 0.977 0.468 5.180 0.065 - - - 
95%_CI_upper_limit 0.98 0.938 0.987 - 0.998 0.690 77.764 0.130 - - - 
             
DKK2 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.973 0.906 1.000 0.892 1.000 0.579 Inf 0.094 0 32 0.906 
95%_CI_lower_limit 0.958 0.871 0.920 - 0.988 0.467 NaN 0.067 - - - 
95%_CI_upper_limit 0.988 0.933 1.000 - 1.000 0.684 Inf 0.130 - - - 
             
EDNRB 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.916 0.787 0.909 0.900 0.985 0.354 8.652 0.235 4 73 0.696 
95%_CI_lower_limit 0.883 0.740 0.788 - 0.963 0.272 3.393 0.188 - - - 
95%_CI_upper_limit 0.949 0.827 0.964 - 0.994 0.446 22.061 0.294 - - - 
             
EN2 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.984 0.959 1.000 0.737 1.000 0.759 Inf 0.041 0 14 0.959 
95%_CI_lower_limit 0.973 0.932 0.920 - 0.988 0.635 NaN 0.025 - - - 
95%_CI_upper_limit 0.996 0.975 1.000 - 1.000 0.850 Inf 0.068 - - - 
             
FBN1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.967 0.930 1.000 0.780 1.000 0.647 Inf 0.070 0 24 0.930 
95%_CI_lower_limit 0.95 0.898 0.920 - 0.988 0.528 NaN 0.048 - - - 
95%_CI_upper_limit 0.984 0.952 1.000 - 1.000 0.750 Inf 0.103 - - - 
             
             
             
FBN2 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.979 0.942 1.000 0.768 1.000 0.688 Inf 0.058 0 20 0.942 
95%_CI_lower_limit 0.965 0.911 0.920 - 0.988 0.566 NaN 0.038 - - - 
95%_CI_upper_limit 0.992 0.962 1.000 - 1.000 0.788 Inf 0.089 - - - 
             
FNDC1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.957 0.898 1.000 0.886 1.000 0.557 Inf 0.102 0 35 0.898 
95%_CI_lower_limit 0.937 0.861 0.920 - 0.988 0.447 NaN 0.075 - - - 
95%_CI_upper_limit 0.977 0.925 1.000 - 1.000 0.661 Inf 0.140 - - - 
             
GAD2 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.961 0.863 1.000 0.929 1.000 0.484 Inf 0.137 0 47 0.863 
95%_CI_lower_limit 0.943 0.822 0.920 - 0.987 0.384 NaN 0.105 - - - 
95%_CI_upper_limit 0.979 0.895 1.000 - 1.000 0.585 Inf 0.179 - - - 
             
GHSR 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.965 0.880 0.977 0.901 0.997 0.512 38.725 0.123 1 41 0.857 
95%_CI_lower_limit 0.948 0.841 0.882 - 0.981 0.407 5.576 0.092 - - - 
95%_CI_upper_limit 0.982 0.910 0.996 - 0.999 0.616 268.929 0.164 - - - 
             
GLRB 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.972 0.956 1.000 0.724 1.000 0.746 Inf 0.044 0 15 0.956 
95%_CI_lower_limit 0.955 0.929 0.920 - 0.988 0.622 NaN 0.027 - - - 
95%_CI_upper_limit 0.988 0.973 1.000 - 1.000 0.839 Inf 0.072 - - - 
             
GNG7 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.971 0.930 0.977 0.810 0.997 0.642 40.912 0.072 1 24 0.907 
95%_CI_lower_limit 0.956 0.898 0.882 - 0.982 0.522 5.892 0.049 - - - 
95%_CI_upper_limit 0.986 0.952 0.996 - 0.999 0.746 284.068 0.106 - - - 
             
GRIA4 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.984 0.962 1.000 0.762 1.000 0.772 Inf 0.038 0 13 0.962 
95%_CI_lower_limit 0.973 0.936 0.920 - 0.988 0.648 NaN 0.022 - - - 
95%_CI_upper_limit 0.995 0.978 1.000 - 1.000 0.862 Inf 0.065 - - - 
             
GRIK3 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.968 0.901 1.000 0.903 1.000 0.564 Inf 0.099 0 34 0.901 
95%_CI_lower_limit 0.951 0.864 0.920 - 0.988 0.454 NaN 0.072 - - - 
95%_CI_upper_limit 0.984 0.928 1.000 - 1.000 0.669 Inf 0.137 - - - 
             
GRIN2D 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.983 0.974 1.000 0.730 1.000 0.830 Inf 0.026 0 9 0.974 
95%_CI_lower_limit 0.97 0.951 0.920 - 0.989 0.708 NaN 0.014 - - - 
95%_CI_upper_limit 0.996 0.986 1.000 - 1.000 0.908 Inf 0.050 - - - 
             
             
             
GRIN2D_1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.995 0.974 0.955 0.785 0.994 0.824 21.421 0.028 2 9 0.928 
95%_CI_lower_limit 0.991 0.951 0.849 - 0.978 0.697 5.530 0.014 - - - 
95%_CI_upper_limit 1 0.986 0.987 - 0.998 0.904 82.974 0.053 - - - 
             
GRIN2D_2 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.987 0.965 1.000 0.836 1.000 0.786 Inf 0.035 0 12 0.965 
95%_CI_lower_limit 0.976 0.940 0.920 - 0.988 0.662 NaN 0.020 - - - 
95%_CI_upper_limit 0.997 0.980 1.000 - 1.000 0.873 Inf 0.061 - - - 
             
GRIN3B 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.899 0.848 0.886 0.841 0.983 0.429 7.462 0.172 5 52 0.734 
95%_CI_lower_limit 0.867 0.806 0.760 - 0.961 0.332 3.265 0.131 - - - 
95%_CI_upper_limit 0.932 0.882 0.950 - 0.993 0.531 17.052 0.225 - - - 
             
GRM6 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.928 0.699 1.000 0.956 1.000 0.299 Inf 0.301 0 103 0.699 
95%_CI_lower_limit 0.897 0.648 0.920 - 0.984 0.231 NaN 0.256 - - - 
95%_CI_upper_limit 0.958 0.745 1.000 - 1.000 0.378 Inf 0.354 - - - 
             
GRM7 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.956 0.789 1.000 0.941 1.000 0.379 Inf 0.211 0 72 0.789 
95%_CI_lower_limit 0.934 0.743 0.920 - 0.986 0.296 NaN 0.171 - - - 
95%_CI_upper_limit 0.977 0.829 1.000 - 1.000 0.470 Inf 0.258 - - - 
             
HAPLN4 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.962 0.895 1.000 0.872 1.000 0.550 Inf 0.105 0 36 0.895 
95%_CI_lower_limit 0.944 0.858 0.920 - 0.988 0.441 NaN 0.077 - - - 
95%_CI_upper_limit 0.98 0.923 1.000 - 1.000 0.654 Inf 0.143 - - - 
             
HTR1E 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.955 0.883 1.000 0.900 1.000 0.524 Inf 0.117 0 40 0.883 
95%_CI_lower_limit 0.936 0.845 0.920 - 0.987 0.418 NaN 0.087 - - - 
95%_CI_upper_limit 0.975 0.913 1.000 - 1.000 0.627 Inf 0.156 - - - 
             
ITGA4 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.991 0.962 0.977 0.833 0.997 0.768 42.327 0.039 1 13 0.939 
95%_CI_lower_limit 0.982 0.936 0.882 - 0.983 0.642 6.097 0.023 - - - 
95%_CI_upper_limit 0.999 0.978 0.996 - 0.999 0.859 293.863 0.066 - - - 
             
ITGA8 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.975 0.912 0.977 0.869 0.997 0.589 40.140 0.090 1 30 0.890 
95%_CI_lower_limit 0.961 0.878 0.882 - 0.982 0.474 5.781 0.064 - - - 
95%_CI_upper_limit 0.989 0.938 0.996 - 0.999 0.695 278.725 0.127 - - - 
             
             
             
JAM3 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.975 0.927 1.000 0.818 1.000 0.638 Inf 0.073 0 25 0.927 
95%_CI_lower_limit 0.961 0.894 0.920 - 0.988 0.520 NaN 0.050 - - - 
95%_CI_upper_limit 0.989 0.950 1.000 - 1.000 0.741 Inf 0.107 - - - 
             
KCNA1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.974 0.904 1.000 0.922 1.000 0.571 Inf 0.096 0 33 0.904 
95%_CI_lower_limit 0.96 0.868 0.920 - 0.988 0.460 NaN 0.070 - - - 
95%_CI_upper_limit 0.988 0.930 1.000 - 1.000 0.676 Inf 0.133 - - - 
             
KCNA3 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.979 0.939 0.977 0.875 0.997 0.672 41.298 0.063 1 21 0.916 
95%_CI_lower_limit 0.966 0.908 0.882 - 0.983 0.550 5.948 0.041 - - - 
95%_CI_upper_limit 0.992 0.959 0.996 - 0.999 0.774 286.739 0.095 - - - 
             
KCNQ5 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.983 0.942 1.000 0.852 1.000 0.688 Inf 0.058 0 20 0.942 
95%_CI_lower_limit 0.972 0.911 0.920 - 0.988 0.566 NaN 0.038 - - - 
95%_CI_upper_limit 0.995 0.962 1.000 - 1.000 0.788 Inf 0.089 - - - 
             
LAMA1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.977 0.939 0.955 0.852 0.994 0.667 20.649 0.064 2 21 0.893 
95%_CI_lower_limit 0.963 0.908 0.849 - 0.978 0.544 5.330 0.042 - - - 
95%_CI_upper_limit 0.991 0.959 0.987 - 0.998 0.771 79.997 0.098 - - - 
             
LHCGR 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.923 0.798 1.000 0.911 1.000 0.389 Inf 0.202 0 69 0.798 
95%_CI_lower_limit 0.896 0.753 0.920 - 0.986 0.305 NaN 0.163 - - - 
95%_CI_upper_limit 0.951 0.837 1.000 - 1.000 0.482 Inf 0.249 - - - 
             
MMP9 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.909 0.781 0.955 0.898 0.993 0.359 17.175 0.230 2 75 0.735 
95%_CI_lower_limit 0.878 0.734 0.849 - 0.973 0.278 4.429 0.186 - - - 
95%_CI_upper_limit 0.94 0.821 0.987 - 0.998 0.449 66.599 0.283 - - - 
             
NELL1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.985 0.953 1.000 0.872 1.000 0.733 Inf 0.047 0 16 0.953 
95%_CI_lower_limit 0.974 0.925 0.920 - 0.988 0.610 NaN 0.029 - - - 
95%_CI_upper_limit 0.995 0.971 1.000 - 1.000 0.829 Inf 0.075 - - - 
             
NOS1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.967 0.924 0.977 0.837 0.997 0.623 40.655 0.078 1 26 0.901 
95%_CI_lower_limit 0.951 0.891 0.882 - 0.982 0.505 5.855 0.054 - - - 
95%_CI_upper_limit 0.984 0.948 0.996 - 0.999 0.728 282.287 0.113 - - - 
             
             
             
NPBWR1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.988 0.971 1.000 0.787 1.000 0.815 Inf 0.029 0 10 0.971 
95%_CI_lower_limit 0.978 0.947 0.920 - 0.989 0.692 NaN 0.016 - - - 
95%_CI_upper_limit 0.998 0.984 1.000 - 1.000 0.896 Inf 0.054 - - - 
             
NPY2R 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.97 0.909 0.955 0.851 0.994 0.575 20.006 0.095 2 31 0.864 
95%_CI_lower_limit 0.953 0.874 0.849 - 0.977 0.461 5.163 0.067 - - - 
95%_CI_upper_limit 0.986 0.935 0.987 - 0.998 0.682 77.515 0.134 - - - 
             
OPRK1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.963 0.918 0.955 0.848 0.994 0.600 20.199 0.086 2 28 0.873 
95%_CI_lower_limit 0.946 0.884 0.849 - 0.977 0.483 5.213 0.060 - - - 
95%_CI_upper_limit 0.981 0.943 0.987 - 0.998 0.707 78.260 0.123 - - - 
             
PCDHG. 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.978 0.965 0.977 0.798 0.997 0.782 42.456 0.036 1 12 0.942 
95%_CI_lower_limit 0.964 0.940 0.882 - 0.983 0.656 6.115 0.021 - - - 
95%_CI_upper_limit 0.992 0.980 0.996 - 0.999 0.871 294.754 0.063 - - - 
             
PCDHG._1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.996 0.962 1.000 0.922 1.000 0.772 Inf 0.038 0 13 0.962 
95%_CI_lower_limit 0.99 0.936 0.920 - 0.988 0.648 NaN 0.022 - - - 
95%_CI_upper_limit 1.001 0.978 1.000 - 1.000 0.862 Inf 0.065 - - - 
             
PLCB1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.892 0.769 0.977 0.846 0.996 0.352 33.836 0.236 1 79 0.746 
95%_CI_lower_limit 0.86 0.721 0.882 - 0.979 0.273 4.870 0.194 - - - 
95%_CI_upper_limit 0.924 0.811 0.996 - 0.999 0.441 235.090 0.288 - - - 
             
PRKAR1B 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.986 0.956 1.000 0.853 1.000 0.746 Inf 0.044 0 15 0.956 
95%_CI_lower_limit 0.974 0.929 0.920 - 0.988 0.622 NaN 0.027 - - - 
95%_CI_upper_limit 0.997 0.973 1.000 - 1.000 0.839 Inf 0.072 - - - 
             
PRKCB 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.961 0.904 0.977 0.810 0.997 0.566 39.754 0.099 1 33 0.881 
95%_CI_lower_limit 0.943 0.868 0.882 - 0.982 0.454 5.725 0.071 - - - 
95%_CI_upper_limit 0.979 0.930 0.996 - 0.999 0.671 276.053 0.137 - - - 
             
PTGFR 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.932 0.819 0.955 0.906 0.993 0.404 18.012 0.190 2 62 0.773 
95%_CI_lower_limit 0.906 0.774 0.849 - 0.975 0.315 4.646 0.150 - - - 
95%_CI_upper_limit 0.959 0.856 0.987 - 0.998 0.500 69.824 0.240 - - - 
             
             
             
RSPO2 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.987 0.947 0.977 0.882 0.997 0.705 41.684 0.054 1 18 0.925 
95%_CI_lower_limit 0.977 0.918 0.882 - 0.983 0.581 6.004 0.034 - - - 
95%_CI_upper_limit 0.996 0.966 0.996 - 0.999 0.804 289.411 0.085 - - - 
             
RSPO3 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.947 0.895 0.977 0.871 0.997 0.544 39.368 0.108 1 36 0.872 
95%_CI_lower_limit 0.925 0.858 0.882 - 0.982 0.435 5.669 0.079 - - - 
95%_CI_upper_limit 0.969 0.923 0.996 - 0.999 0.650 273.382 0.147 - - - 
             
SCTR 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.964 0.930 1.000 0.771 1.000 0.647 Inf 0.070 0 24 0.930 
95%_CI_lower_limit 0.946 0.898 0.920 - 0.988 0.528 NaN 0.048 - - - 
95%_CI_upper_limit 0.982 0.952 1.000 - 1.000 0.750 Inf 0.103 - - - 
             
SDC2 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.962 0.936 0.977 0.615 0.997 0.662 41.170 0.066 1 22 0.913 
95%_CI_lower_limit 0.944 0.905 0.882 - 0.983 0.540 5.929 0.044 - - - 
95%_CI_upper_limit 0.981 0.957 0.996 - 0.999 0.765 285.849 0.099 - - - 
             
SFRP1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.983 0.944 1.000 0.862 1.000 0.698 Inf 0.056 0 19 0.944 
95%_CI_lower_limit 0.972 0.915 0.920 - 0.988 0.576 NaN 0.036 - - - 
95%_CI_upper_limit 0.994 0.964 1.000 - 1.000 0.798 Inf 0.086 - - - 
             
SFRP2 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.964 0.933 1.000 0.754 1.000 0.657 Inf 0.067 0 23 0.933 
95%_CI_lower_limit 0.945 0.901 0.920 - 0.988 0.537 NaN 0.045 - - - 
95%_CI_upper_limit 0.982 0.955 1.000 - 1.000 0.759 Inf 0.100 - - - 
             
SHANK1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.939 0.860 0.955 0.873 0.993 0.467 18.912 0.147 2 48 0.814 
95%_CI_lower_limit 0.915 0.819 0.849 - 0.976 0.367 4.880 0.112 - - - 
95%_CI_upper_limit 0.962 0.892 0.987 - 0.998 0.569 73.298 0.193 - - - 
             
SLC12A5 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.93 0.751 0.977 0.936 0.996 0.336 33.064 0.254 1 85 0.729 
95%_CI_lower_limit 0.901 0.703 0.882 - 0.978 0.260 4.759 0.210 - - - 
95%_CI_upper_limit 0.959 0.794 0.996 - 0.999 0.421 229.747 0.307 - - - 
             
SLC18A3 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.97 0.939 0.977 0.815 0.997 0.672 41.298 0.063 1 21 0.916 
95%_CI_lower_limit 0.955 0.908 0.882 - 0.983 0.550 5.948 0.041 - - - 
95%_CI_upper_limit 0.986 0.959 0.996 - 0.999 0.774 286.739 0.095 - - - 
             
             
             
SLC32A1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.978 0.915 1.000 0.893 1.000 0.603 Inf 0.085 0 29 0.915 
95%_CI_lower_limit 0.965 0.881 0.920 - 0.988 0.488 NaN 0.060 - - - 
95%_CI_upper_limit 0.991 0.940 1.000 - 1.000 0.707 Inf 0.120 - - - 
             
SLC5A7 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.944 0.863 0.955 0.870 0.993 0.472 18.977 0.144 2 47 0.817 
95%_CI_lower_limit 0.921 0.822 0.849 - 0.976 0.372 4.896 0.110 - - - 
95%_CI_upper_limit 0.966 0.895 0.987 - 0.998 0.575 73.546 0.189 - - - 
             
SLC6A1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.973 0.918 1.000 0.808 1.000 0.611 Inf 0.082 0 28 0.918 
95%_CI_lower_limit 0.959 0.884 0.920 - 0.988 0.496 NaN 0.057 - - - 
95%_CI_upper_limit 0.988 0.943 1.000 - 1.000 0.715 Inf 0.117 - - - 
             
SLC6A11 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.973 0.883 0.977 0.907 0.997 0.518 38.854 0.120 1 40 0.860 
95%_CI_lower_limit 0.958 0.845 0.882 - 0.982 0.412 5.595 0.089 - - - 
95%_CI_upper_limit 0.988 0.913 0.996 - 0.999 0.622 269.820 0.161 - - - 
             
SLC6A3 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.984 0.921 1.000 0.874 1.000 0.620 Inf 0.079 0 27 0.921 
95%_CI_lower_limit 0.973 0.888 0.920 - 0.988 0.503 NaN 0.055 - - - 
95%_CI_upper_limit 0.994 0.945 1.000 - 1.000 0.724 Inf 0.113 - - - 
             
SLC8A1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.965 0.918 0.955 0.828 0.994 0.600 20.199 0.086 2 28 0.873 
95%_CI_lower_limit 0.949 0.884 0.849 - 0.977 0.483 5.213 0.060 - - - 
95%_CI_upper_limit 0.982 0.943 0.987 - 0.998 0.707 78.260 0.123 - - - 
             
SLIT3 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.964 0.918 1.000 0.870 1.000 0.611 Inf 0.082 0 28 0.918 
95%_CI_lower_limit 0.946 0.884 0.920 - 0.988 0.496 NaN 0.057 - - - 
95%_CI_upper_limit 0.981 0.943 1.000 - 1.000 0.715 Inf 0.117 - - - 
             
SPOCK1 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.98 0.953 1.000 0.760 1.000 0.733 Inf 0.047 0 16 0.953 
95%_CI_lower_limit 0.967 0.925 0.920 - 0.988 0.610 NaN 0.029 - - - 
95%_CI_upper_limit 0.993 0.971 1.000 - 1.000 0.829 Inf 0.075 - - - 
             
SYN3 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.969 0.906 1.000 0.896 1.000 0.579 Inf 0.094 0 32 0.906 
95%_CI_lower_limit 0.952 0.871 0.920 - 0.988 0.467 NaN 0.067 - - - 
95%_CI_upper_limit 0.985 0.933 1.000 - 1.000 0.684 Inf 0.130 - - - 
             
             
             
VCAN 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.927 0.860 1.000 0.854 1.000 0.478 Inf 0.140 0 48 0.860 
95%_CI_lower_limit 0.901 0.819 0.920 - 0.987 0.379 NaN 0.108 - - - 
95%_CI_upper_limit 0.952 0.892 1.000 - 1.000 0.579 Inf 0.182 - - - 
             
VIPR2 
 
AUC Se Sp cutoff PPV NPV DLR Positive 
DLR 







Estimate 0.99 0.971 1.000 0.867 1.000 0.815 Inf 0.029 0 10 0.971 
95%_CI_lower_limit 0.981 0.947 0.920 - 0.989 0.692 NaN 0.016 - - - 
95%_CI_upper_limit 0.998 0.984 1.000 - 1.000 0.896 Inf 0.054 - - - 
 
 
AUC: Area Under the ROC curve  
Se: sensitivity  
Sp: specificity  
cutoff: individuals with a test value lower than the cutoff are classified as healthy (negative test), whereas patients 
with a test value greater than (or equal to) the cutoff are classified as diseased (positive test). The estimation of the 
optimal cutoff has been evalueted using the Youden index method that gives equal weight to sensitivity and 
specificity.  
PPV: positive predictive value  
NPV: negative predictive value  
DLR.Positive: positive diagnostic likelihood ratio  
DLR.Negative: negative diagnostic likelihood ratio  
FP: false positive  
FN: false negative  
Optimal_criterion: the numerical value of the criterion (Youden index) at the optimal cutpoint  
 
Supporting Information Table 9: Clinical features of the forty five CRC cases enrolled for cell 
free DNA samples analysed by methyl-BEAMing1 
Patient 














CP26 M 58 II Metastatic patient 1.1 
BRAF 
mutated 0 5+  
CP15 M 71 III Metastatic patient 2.2 Wilde Type X 5+ no 
CP28 M 68 IV Metastatic patient 2.9 Wilde Type X 5+ yes 
CP27 M 80 II Metastatic patient 1.7 
KRAS 
mutated 0 5+ no 
CP47 F 72 IV Metastatic patient 2.9 Wilde Type X 5+ yes 
CP25 M 80 III Metastatic patient 0.9 
KRAS 
mutated 0  no 
CP18 M 57 IV Metastatic patient 1.9 Wilde Type X 5 no 
CP16 F 59 IV Metastatic patient 1.8 
KRAS 
mutated 0 1 no 
CP52 F 64 III Metastatic patient 4.7 
BRAF 
mutated 0 5+ no 
CP19 M 74 IV Metastatic patient 1.4 
KRAS 
mutated 0 5+ yes 
CP30 M 69 II Metastatic patient 1.9 Wilde Type X 4 no 
CP24 M 69 IV Metastatic patient 4.1 
KRAS 
mutated 0 5+ no 
CP06 M 63 III Metastatic patient 3.7 
KRAS 
mutated 0 2 no 
CP01 M 71 IV Metastatic patient 4.4 Wilde Type X 5+ no 
CP51 F 62 III Metastatic patient 1.5 
KRAS 
mutated 0  no 
CP02 M 49 IV Metastatic patient 64.7 
KRAS 
mutated 17 5+ no 
CP04 M 70 IV Metastatic patient 50.1 
KRAS 
mutated 12.4 5+ no 
CP05 M 62 IV Metastatic patient 47.5 Wilde Type X 4 no 
CP11 M 74 IV Metastatic patient 36.2 
KRAS 
mutated 0.11 11+ yes 
CP12 M 63 IV Metastatic patient 73.7 
KRAS 
mutated 13.2 5 + yes 
CP13 F 67 IV Metastatic patient 8.3 
KRAS 
mutated 0 5+ no 
CP14 F 71 IV Metastatic patient 896.3 
KRAS 
mutated 0 5+ no 
CP31 F 71 IV Metastatic patient 46.6 Wilde Type X 5+ no 
CP33 F 56 IV Metastatic patient 9.7 Wilde Type X 5+ yes 
CP35 F 69 IV Metastatic patient 18.6 Wilde Type X 5+ yes 
CP36 M 69 IV Metastatic patient 262.5 
KRAS 
mutated 33 5+ yes 
CP38 F 83 IV Metastatic patient 146.5 
KRAS 
mutated 0 5+ no 
CP39 F 70 III Metastatic patient 15.4 Wilde Type X  no 
CP40 M 43 IIIc Metastatic patient 10.5 
KRAS 
mutated 0 
4 (+ lymph 
nodes) yes 
CP49 F 76 IV Metastatic patient 2396 Wilde Type X  no 
CP50 M 66 IV Metastatic patient 46.7 
KRAS 
mutated 2 5+ no 
CP53 M 69 IV Metastatic patient 417.9 
KRAS 
mutated 3 5+ no 
CP54 F 67 IV Metastatic patient 25.1 
KRAS 
mutated 1.9 5+ yes 
CP03 F 64 III NED patient 1.2 Wilde Type X  no 
CP07 F 69 III NED patient 1.8 Wilde Type X  no 
CP09 M 59 II NED patient 2.9 Wilde Type X  no 
CP10 M 65 IV NED patient 20.4 
KRAS 
mutated 0 2 yes 
CP17 F 59 III NED patient 3.5 
BRAF 
mutated 0  no 
CP20 M 72 IV NED patient 2.3 Wilde Type X  no 
CP21 M 56 III NED patient 3.8 
KRAS 
mutated 0  no 
CP23 F 56 II NED patient 3.1 Wilde Type X  no 
CP29 M 52 IV NED patient 3.1 
KRAS 
mutated 0 1 no 
CP32 M 57 III NED patient 24.3 Wilde Type X  yes 
CP34 M 46 II NED patient NA NA X  no 
CP55 M 79 III NED patient 28.2 NA X   
 
1
 The primer sequences are reported in Appendix Table S8. More protocol details can be found in references 
16 and 17. 
2
 All DNA samples were treated with sodium bisulfite using the EZ DNA Methylation Gold Kit ™ (Zymo 
Research). 
 
Supporting Information Table 10: Association between methylation status and cancer of some genes associated to the CpG islands found altered 
in this study 
Gene Name Associated Disease Reference 
ADAMTS5 CRC Kim, Young-Ho, et al. Annals of surgical oncology 18.8 (2011): 2338-2347. doi: 10. 1245/ s10434-011-1573-y 
ADRA1B Bipolar disorder 
Sugawara, Hiroko, et al. Progress in Neuro-Psychopharmacology and Biological Psychiatry 56 (2015): 117-121. doi: 
10.1016/j.pnpbp.2014.08.010 
 
Cell line (SK-N-MC and DU145) Michelotti, Gregory A., et al. The FASEB Journal 21.9 (2007): 1979-1993. doi: 10.1096/fj.06-7118com 
 
Gastric cancer Noda, H., et al. British journal of cancer 96.2 (2007): 383-390. doi:10.1038/sj.bjc.6603555 
CACNA1 Bladder cancer García-Baquero, Rodrigo, et al. Tumor Biology 35.6 (2014): 5777-5786. doi:10. 1007/ s13277-014-1767-6 
 
Bladder cancer García-Baquero, Rodrigo, et al. The Journal of urology 190.2 (2013): 723-730. doi:10.1016/j.juro.2013.01.105 
 
Ovarian clear cell adenocarcinoma (OCCA) Ho, Chih-Ming, et al. Mol Cancer 11 (2012): 53. doi: 10.1186/1476-4598-11-53 
 
Triple-negative breast carcinomas Branham, M. T., et al. Oncogenesis 1.7 (2012): e17. doi:10.1038/oncsis.2012.17 
 
Lung cancer Castro, Mónica, et al. J Transl Med 8.86 (2010): 1479-5876.doi:10. 1186/ 1479-5876-8-86 
 
Prostate cancer Kinney, Shannon R. Morey, et al. Molecular Cancer Research 6.8 (2008): 1365-1374. doi:10.1158/1541-7786.MCR-08-0040 
CDH4 Gastric cancer Zhou, Lin, et al. Cancer biology & therapy 16.8 (2015): 1241-1251. doi:10.1080/15384047.2015.1056411 
 
CRC Nishioka, Y., et al. The International journal of biological markers 30.1 (2014): e81-7. doi:10.5301/jbm.5000099 
 
Gastric cancer Zhou, Lin, et al. The FASEB Journal 27.12 (2013): 4929-4939. doi:10.1096/fj.13-233387 
 
Nasopharyngeal carcinoma Du, Chunping, et al. Cancer letters 309.1 (2011): 54-61. doi:10.1016/j.canlet.2011.05.016 
 
Head and neck squamous cell carcinoma (HNSCC) and Salivary 
rinses 
Demokan, Semra, et al. International Journal of Cancer 127.10 (2010): 2351-2359. doi: 10.1002/ijc.25248 
doi:  10.1002/ijc.25248 
 
Gastric cancer Tani, Nobuyuki, et al. Gan to kagaku ryoho. Cancer & chemotherapy 33.12 (2006): 1720-1722. 
 
Colorectal and Gastric cancer Miotto, Elena, et al. Cancer research 64.22 (2004): doi: 10.1158/0008-5472.CAN-04-30008156-8159. 
CHAT Astrocytomas Wu, Xiwei, et al. Cancer research 70.7 (2010): 2718-2727. doi: 10.1158/0008-5472.CAN-09-3631 
 
Cell lines (NE1-115 cell; NG108-15) Quirin-Stricker, C., et al. Molecular brain research 23.3 (1994): 253-265. doi:10.1016/0169-328X(94)90232-1 
COL23A1 Gastric carcinomas Yamanoi, Kazuhiro, et al. Cancer Research 74.19 Supplement (2014): 1370-1370. doi: 10.1093/carcin/bgv013 
COL4A1 Uterine leiomyomas Maekawa, Ryo, et al. PLoS ONE 8(6): e66632. (2013): e66632. doi:10.1371/journal.pone.0066632 
COL4A2 CRC Mitchell, Susan M., et al. BMC cancer 14.1 (2014): 54. doi:10.1186/1471-2407-14-54 
 
Uterine leiomyomas Maekawa, Ryo, et al. PLoS ONE 8(6): e66632. (2013): e66632. doi:10.1371/journal.pone.0066632 
CREB3L1 Bladder cancer Rose, Michael, et al. Epigenetics 9.12 (2014): 1626-1640. doi: 10.1002/path.4210 
 
Human papillomavirus (hrHPV) Steenbergen, Renske DM, et al. The Journal of pathology 231.1 (2013): 53-62.  doi: 10.1002/path.4210 
DKK 2 Nasopharyngeal carcinoma Li, Lili, et al. Epigenomics 0 (2014): 155-173. doi:10.2217/epi.14.79 
 
CRC Silva, Ana-Luisa, et al. BMC cancer 14.1 (2014): 891. doi: 10.1186/1471-2407-14-891 
 - - - Sinha, Shriprakash. Integrative Biology 6.11 (2014): 1034-1048. doi: 10.1039/C4IB00124A 
 
CRC Harada, Taku, et al. Cancer Prevention Research 7.10 (2014): 1002-1010. doi:10.1158/1940-6207.CAPR-14-0162 
 
CRC Farkas, Sanja A., et al. Epigenomics 6.2 (2014): 179-191. doi:10.2217/epi.14.7 
 
CRC Silva, Tiago Donizetti, et al. Oncology letters 6.6 (2013): 1687-1692. doi: 10.3892/ol.2013.1606 
 
Cholangiocarcinomas Goeppert, Benjamin, et al. Hepatology 59.2 (2014): 544-554. doi: 10.1002/hep.26721 
 
Gastric cancer Suzuki, Ryo, et al. Journal of gastroenterology 49.7 (2014): 1135-1144. doi: 10.1007/s00535-013-0861-7 
 
Medulloblastoma Valdora, Francesca, et al. International journal of molecular sciences 14.4 (2013): 7492-7505. doi: 10.3390/ijms14047492 
 
Ovarian carcinoma Zhu, Jing, et al. Carcinogenesis (2012): bgs278. doi: 10.1093/carcin/bgs278 
 
Primary B cell chronic lymphocytic leukaemia Moskalev, Evgeny A., et al. BMC cancer 12.1 (2012): 213. doi: 10.1186/1471-2407-12-213 
 
Cylindromas/Spiradenomas Rajan, Neil, et al. The Journal of pathology 224.3 (2011): 309-321. doi: 10.1002/path.2896 
 
Lung adenocarcinoma Jung, Il Lae, et al. International journal of molecular medicine 26.1 (2010): 33-38. doi: 10.1002/path.2896 
 
Renal cancer Hirata, Hiroshi, et al. Clinical Cancer Research 15.18 (2009): 5678-5687.  doi: 10.1158/1078-0432 
 
Gastrointestinal cancer Maehata, Tadateru, et al. World journal of gastroenterology: WJG 14.17 (2008): 2702. doi:  10.3748/wjg.14.2702 
 
Gastrointestinal cancer Sato, Hironobu, et al. Carcinogenesis 28.12 (2007): 2459-2466. doi: 10.1093/carcin/bgm178 
 
- - - Katoh, Masuko, and Masaru Katoh. Oncology reports 14.3 (2005): 783-787. 
EDNRB Hepatocellular Carcinoma Chen, Haiyan, et al. Journal of Cancer 6.8 (2015): 740. doi: 10.7150/jca.11691 
 
head and neck squamous cell carcinoma Hayashi, Masamichi, et al. Cancer (2015). DOI: 10.1002/cncr.29303 
 
head and neck squamous cell carcinoma Mydlarz, Wojciech K., et al.  Head & neck (2014). doi: 10.1002/hed.23842 
 
head and neck squamous cell carcinoma Hayashi, Masamichi, et al. Annals of surgical oncology 21.9 (2014): 3124-3131. DOI 10.1245/s10434-014-3661-2 
 
cervical intraepithelial neoplasia Vasiljević, Nataša, et al. Gynecologic oncology 132.3 (2014): 709-714. doi: 10.1016/j.ygyno.2014.02.001 
 
CRC Chen, Cheng, et al. Diagn Pathol 8.1 (2013): 199.  doi: 10.1186/1746-1596-8-199 
prostate/bladder/clear cell renal carcinomas Watanabe, Junko, et al.  Journal of cancer research and clinical oncology 140.1 (2014): 99-107.  doi: 10.1007/s00432-013-1546-6 
 
Gatric cancer 
Qu, Yiping, Siwen Dang, and Peng Hou. "Gene methylation in gastric cancer." Clinica Chimica Acta 424 (2013): 53-65. doi: 
10.1016/j.cca.2013.05.002 
Oral cancer/dysplasia Schussel, Juliana, et al.  Clinical Cancer Research 19.12 (2013): 3268-3275.  doi: 10.1158/1078-0432.CCR-12-3496 
 
head neck cancer Roh, Jong-Lyel, et al.  Clinical Cancer Research (2013).doi: 10.1158/1078-0432.CCR-12-3047 
oral/oropharyngeal squamous cell carcinoma de Freitas Cordeiro-Silva, Melissa, et al. Molecular biology reports 39.12 (2012): 10111-10119. doi: 10.1007/s11033-012-1885-4 
 
head and neck squamous cell carcinoma Roh, Jong–Lyel, et al. Head & neck 34.11 (2012): 1529-1536.  doi: 10.1002/hed.21982 
oral/oropharyngeal squamous cell carcinoma Viet, Chi T., et al.  PAIN® 152.10 (2011): 2323-2332. doi: 10.1016/j.pain.2011.06.025 
 
Non-muscle-invasive bladder cancer Zuiverloon, Tahlita, et al. BJU international 109.6 (2012): 941-948. doi: 10.1111/j.1464-410X.2011.10428.x 
Prostate cancer Vasiljeviš, Nataڑa, et al. Disease markers 30.4 (2011): 151-161. doi: 10.3233/DMA-2011-0790 
 
oral/oropharyngeal squamous cell carcinoma Guerrero-Preston, Rafael, et al.  Cancer prevention research 4.7 (2011): 1061-1072.  doi: 10.1158/1940-6207.CAPR-11-0006 
 oral/oropharyngeal squamous cell carcinoma de Freitas Cordeiro-Silva, Melissa, et al.  Molecular biology reports 38.8 (2011): 5435-5441.  doi: 10.1007/s11033-011-0698-1. 
 
Gastric cancer Tao, Kaixiong, et al.  Medical Oncology 29.1 (2012): 107-112.  doi: 10.1007/s12032-010-9805-8 
 
Glioma De Tayrac, Marie, et al. Clinical Cancer Research 17.2 (2011): 317-327. doi: 10.1158/1078-0432.CCR-10-1126 
 
Oral cancer Pattani, Kavita Malhotra, et al. Cancer Prevention Research 3.9 (2010): 1093-1103. doi: 10.1158/1940-6207.CAPR-10-0115. 
 
oral/oropharyngeal squamous cell carcinoma Kaur, Jatinder, et al.  International Journal of Cancer 127.10 (2010): 2367-2373. doi: 10.1002/ijc.25377. 
 
head and neck carcinogenesis Demokan, Semra, et al. International Journal of Cancer 127.10 (2010): 2351-2359. doi: 10.1002/ijc.25248. 
 
Prostate cancer 
Phé, Veronique, Olivier Cussenot, and Morgan Rouprêt.  BJU international 105.10 (2010): 1364-1370. doi: 10.1111/j.1464-
410X.2009.09167.x 
 
Urothelial cell carcinomas 
Phé, Véronique, Olivier Cussenot, and Morgan Rouprêt. BJU international 104.7 (2009): 896-901. doi: 10.1111/j.1464-
410X.2009.08696.x. 
 
Bladder cancer Wolff, Erika M., et al.  Cancer research 68.15 (2008): 6208-6214.  doi: 10.1158/0008-5472.CAN-07-6616 
 
esophageal squamous cell carcinoma Zhao, B‐J., et al.  Diseases of the Esophagus 22.1 (2009): 55-61.  doi: 10.1111/j.1442-2050.2008.00848.x 
 
leukemia Hsiao, P., et al.  Chinese Journal of Physiology 51.1 (2008): 27. 
 
Prostate cancer Ellinger, Jörg, et al.  Urology 71.1 (2008): 161-167. doi: 10.1016/j.urology.2007.09.056 
 
Nasopharyngeal carcinoma Zhou, Liang, et al.  Oncology 72.5-6 (2007): 357-363. doi: 10.1159/000113146. 
 
Prostate cancer Bastian, Patrick J., et al.  The Journal of urology 179.2 (2008): 529-535. doi:10.1016/j.juro.2007.09.038 
 
Non-muscle-invasive bladder cancer Friedrich, M. G., et al.  Der Urologe. Ausg. A 46.7 (2007): 761-768. DOI: 10.1007/s00120-007-1360-3 
 
Bladder cancer Yates, David R., et al.  Clinical Cancer Research 13.7 (2007): 2046-2053. doi: 10.1158/1078-0432.CCR-06-2476 
 
Prostate cancer Rogers, Craig G., et al.  The Journal of urology 176.5 (2006): 2280-2284. doi:10.1016/j.juro.2006.07.047 
 
endometrial carcinoma Zhu, J. Z., et al.  Zhonghua bing li xue za zhi Chinese journal of pathology 35.8 (2006): 489. 
 
Prostate cancer Bastian, Patrick J., et al. European urology 51.3 (2007): 665-674. doi:10.1016/j.eururo.2006.08.008 
 
Renal cancer Pflug, Beth R., et al.  Cancer letters 246.1 (2007): 139-148. doi:10.1016/j.canlet.2006.02.007 
Hepatocellular Carcinoma Hsu, Li-Sung, et al.  Oncology reports 15.2 (2006): 507-511.DOI: 10.3892/or.15.2.507 
 
Lung cancer Chen, Shu-Chen, et al.  Oncology reports 15.1 (2006): 167-172. DOI: 10.3892/or.15.1.167 
Non-muscle-invasive bladder cancer Friedrich, Martin G., et al.  European Journal of Cancer 41.17 (2005): 2769-2778. doi:10.1016/j.ejca.2005.07.019 
 
Bladder cancer Friedrich, Martin G., et al.  Clinical Cancer Research 10.22 (2004): 7457-7465. doi: 10.1158/1078-0432.CCR-04-0930 
Prostate cancer Singal, Rakesh, et al.  Oncology reports 12.3 (2004): 631-637. DOI: 10.3892/or.12.3.631 
 
Prostate cancer Woodson, Karen, et al.  The Prostate 60.1 (2004): 25-31. DOI: 10.1002/pros.20013 
Prostate cancer Woodson, Karen, Jeffrey Hanson, and Joseph Tangrea. Cancer letters 205.2 (2004): 181-188. doi:10.1016/j.canlet.2003.11.027 
 
Prostate cancer Yegnasubramanian, Srinivasan, et al.  Cancer research 64.6 (2004): 1975-1986. doi: 10.1158/0008-5472.CAN-03-3972 
Medulloblastoma Lindsey, Janet C., et al.  Carcinogenesis 25.5 (2004): 661-668. doi: 10.1093/carcin/bgh055 
 
Prostate adenocarcinoma Jeronimo, C., et al.  Journal of clinical pathology 56.1 (2003): 52-55. doi:10.1136/jcp.56.1.52 
Nasopharyngeal carcinoma Lo, Kwok‐Wai, et al.  International journal of cancer 98.5 (2002): 651-655. doi:10.1136/jcp.56.1.52 
 Bladder/Colon/Prostate cancer Pao, Martha M., et al. Human molecular genetics 10.9 (2001): 903-910. doi:10.1136/jcp.56.1.52 
 
Prostate cancer Nelson, Joel B., et al.  Cancer research 57.1 (1997): 35-37. 
EN2 Myelogenous leukemia Abollo-Jiménez, Fernando, et al.  Cell Cycle 13.11 (2014): 1717-1726. doi: 10.4161/cc.28629 
 
Pilocytic astrocytomas Lambert, Sally R., et al.  Acta neuropathologica 126.2 (2013): 291-301. doi: 10.1007/s00401-013-1124-7 
 
renal cancer Slater, Amy A., et al.  Epigenetics 8.3 (2013): 252-267. doi: 10.4161/epi.23817 
 
follicular limphoma Bennett, Lynda B., et al. Genes, Chromosomes and Cancer 48.9 (2009): 828-841.  doi: 10.1002/gcc.20687. 
FBN1 CRC Li, Wen-han, et al.  Disease markers (2015). doi: 10.1155/2015/657570 
 
cholangiocarcinoma Andresen, Kim, et al.  Hepatology 61.5 (2015): 1651-1659.  doi: 10.1002/hep.27707 
 
CRC Bethge, Nicole, et al.  Epigenetics 9.3 (2014): 428-436. doi: 10.4161/epi.27554 
 
CRC Guo, Qi, et al.  Medical Oncology 30.4 (2013): 1-5.  doi: 10.1007/s12032-013-0695-4 
 
CRC/Adenomas Lind, Guro E., et al.  Mol Cancer 10 (2011): 85. doi: 10.1186/1476-4598-10-85. 
 
Prostate cancer WANG, YIPENG, et al.  Annals of the New York Academy of Sciences 1058.1 (2005): 162-185. DOI: 10.1196/annals.1359.024 
 
Prostate cancer cell lines Wang, Yipeng, et al.  Neoplasia 7.8 (2005): 748-IN7. doi:10.1593/neo.05289 
FBN2 clear cell renal cell carcinoma Ricketts, Christopher J., Victoria K. Hill, and W. Marston Linehan.  (2014): e85621. doi: 10.1371/journal.pone.0085621 
 
CRC Kim, Tae-Oh, et al. International journal of molecular medicine 31.5 (2013): 1255-1261.  doi: 10.3892/ijmm.2013.1317. 
 
CRC Hibi, Kenji, et al.  Anticancer research 32.10 (2012): 4371-4374. 
 
Breast carcinoma Kikuyama, Mizuho, et al. Cancer letters 322.2 (2012): 204-212.  doi: 10.1016/j.canlet.2012.03.016 
 
CRC Yi, Joo Mi, et al.  Tumor Biology 33.2 (2012): 363-372. doi: 10.1007/s13277-011-0302-2 
 
Renal cell carcinoma Morris, Mark R., et al.  Oncogene 30.12 (2011): 1390-1401. doi: 10.1038/onc.2010.525 
 
CRC Yagi, Koichi, et al.  Clinical Cancer Research 16.1 (2010): 21-33. doi: 10.1158/1078-0432.CCR-09-2006 
 
esophageal squamous cell carcinoma Tsunoda, Shigeru, et al.  Oncology reports 21.4 (2009): 1067-1073. 
Lung cancer 
Cortese, Rene, et al.  The international journal of biochemistry & cell biology 40.8 (2008): 1494-1508.  doi: 
10.1016/j.biocel.2007.11.018 
 
non-small cell lung cancer Chen, Hong, et al. Lung Cancer 50.1 (2005): 43-49. 
pancreatic cancer Hagihara, Atsushi, et al. Oncogene 23.53 (2004): 8705-8710. 
GAD2 CRC Li, Hai, et al. Oncology reports 28.1 (2012): 99-104. doi: 10.3892/or.2012.1779 
follicular limphoma Bennett, Lynda B., et al. Genes, Chromosomes and Cancer 48.9 (2009): 828-841. doi: 10.1002/gcc.20687 
GHSR 
lung/breast/prostate/pancreas/CRC/glioblastoma/B cell chronic 
lymphocytic leukaemia Moskalev, Evgeny A., et al.  Oncotarget 6.6 (2015): 4418. 
 
Breast carcinoma de Groot, Jolien S., et al.  Cellular Oncology 37.4 (2014): 297-303.doi: 10.1007/s13402-014-0189-1 
Breast carcinoma Botla, Sandeep Kumar, et al.  Breast cancer research and treatment 135.3 (2012): 705-713. doi: 10.1007/s10549-012-2197-z 
 
Breast carcinoma Ordway, Jared M., et al.  PLoS One 2.12 (2007): e1314. 
GNG7 head and neck cancer Demokan, Semra, et al.  International journal of oncology 42.4 (2013): 1427-1436. doi: 10.3892/ijo.2013.1808 
 head and neck squamous cell carcinoma Hartmann, Sylvia, et al.  Journal of applied genetics 53.2 (2012): 167-174.  doi: 10.1007/s13353-011-0079-4 
 
oesophageal cancer Ohta, M., et al.  British journal of cancer 98.2 (2008): 410-417. doi: 10.1038/sj.bjc.6604124 
GRIA4 oropharyngeal squamous cell carcinomas Kostareli, Efterpi, et al.  The Journal of clinical investigation 123.6 (2013): 2488.  doi: 10.1172/JCI67010 
 
follicular limphoma Bennett, Lynda B., et al. Genes, Chromosomes and Cancer 48.9 (2009): 828-841. doi: 10.1002/gcc.20687 
GRIK3 lung adenocarcinoma 
Pradhan, Meeta P., Akshay Desai, and Mathew J. Palakal.  BMC systems biology 7.1 (2013): 141.  doi: 10.1186/1752-0509-7-
141 
GRM6 clear cell renal cell carcinoma Arai, Eri, et al. Carcinogenesis 33.8 (2012): 1487-1493. doi: 10.1093/carcin/bgs177 
GRM7 Chronic lymphocytic leukemia Rush, Laura J., et al.  Cancer research 64.7 (2004): 2424-2433. 
HRH2 Gastric cancer Nomura, Tomoe, et al. BMC gastroenterology 13.1 (2013): 1. doi: 10.1186/1471-230X-13-1 
 
pancreatic cancer Ginestà, Mireia M., et al.  Journal of clinical pathology (2012): jclinpath-2012. doi: 10.1136/jclinpath-2012-201123 
ITGA4 Colitis-associated cancer Gerecke, Christian, et al.  Journal of cancer research and clinical oncology (2015): 1-11. 
 
CRC/Adenomas Zhang, Xie, et al.  World journal of gastroenterology: WJG 21.9 (2015): 2629.  doi: 10.3748/wjg.v21.i9.2629 
 
Prostate cancer Mostafavi-Pour, Z., et al.  Pathology & Oncology Research (2015): 1-7.  doi: 10.1007/s12253-015-9917-8 
 
Breast carcinoma Do, Sung-Im, et al.  Tumor Biology 35.7 (2014): 7079-7084.  doi: 10.1007/s13277-014-1952-7 
 
cervical cancer Hansel, Alfred, et al. PloS one 9.3 (2014): e91905. doi: 10.1371/journal.pone.0091905 
 
lymphocytic leukemia cells Zucchetto, Antonella, et al. Blood 122.19 (2013): 3317-3321. doi: 10.1182/blood-2013-06-507335 
 
Gastric cancer Qu, Yiping, Siwen Dang, and Peng Hou.  Clinica Chimica Acta 424 (2013): 53-65. doi: 10.1016/j.cca.2013.05.002 
 
CRC Ahmed, Deeqa, et al.  Clinical and translational gastroenterology 3.12 (2012): e27.  doi: 10.1038/ctg.2012.21 
 
Breast carcinoma Lian, Zhen-Qiang, et al.  International journal of oncology 41.2 (2012): 629-638. doi: 10.3892/ijo.2012.1464 
 
CRC Chang, Eugene, et al.  Hepato-gastroenterology 57.101 (2009): 720-727. 
 
cholangiocarcinoma 
Uhm, Kyung-Ok, et al. Journal of cancer research and clinical oncology 136.2 (2010): 187-194. doi: 10.1007/s00432-009-0646-
9. 
acute myeloid leukemia (AML) and chronic myeloid leukemia 
(CML) Uhm, Kyung-Ok, et al. Journal of Korean medical science 24.3 (2009): 493-497.  doi: 10.3346/jkms.2009.24.3.493. 
 
Colorectal polyp Ausch, Christoph, et al.  Clinical chemistry 55.8 (2009): 1559-1563. doi: 10.1373/clinchem.2008.122937 
Gastric cancer Kim, Ji Hun, et al.  Oncology reports 21.5 (2009): 1251-1259. 
 
hepatocellular carcinoma 
Ko, Eunkyung, et al. Cancer Epidemiology Biomarkers & Prevention 17.9 (2008): 2260-2267. doi: 10.1158/1055-9965.EPI-08-
0236 
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Gastric cancer Park, Jinah, et al. Oncogene 23.19 (2004): 3474-3480. 
 
fibrosarcoma cell lines Sato, Shuichi, et al. Oncogene 17.1 (1998): 105-113. 
Mouse liver tumors Akama, Tomoya O., et al.  Cancer research 57.15 (1997): 3294-3299. 
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Supplementary Materials and methods 
 
DNA extraction and bisulfite conversion from tissue samples 
Genomic DNA was extracted from tumoral and peritumoral tissue using the DNeasy Blood & 
Tissue Kit (Qiagen) and bisulfite converted using EZ DNA Methylation Gold Kit ™ (Zymo 
Research) according to the manufacturer's instructions. Quality control and quantification of DNA 
were performed before and after bisulfite conversion. DNA was quantified with NanoDrop 
(NanoDrop Products Thermo Scientific Wilmington, DE) and by fluorometric reading (Quant-iT™ 
PicoGreen® dsDNA Assay Kit); quality was assessed by visualisation of genomic DNA on 1% 
agarose gel electrophoresis. Only DNA samples not fragmented and with a concentration higher 
than 50 ng/μl were subsequently processed.  
Samples for pyrosequencing methylation validation 
A validation of GRIA4, SLC8A1, SYN3 CpG islands hypermethylation was performed in 78 CRCs 
and the respective 78 peritumoral samples. Tissue samples were collected at the Department of 
Surgical Sciences, University of Cagliari (Italy) (Figure 1). 
Samples for transcriptome analysis 
RNA was extracted from remaining tissue available from the first methylome step using the 
RNeasy Lipid Tissue Mini Kit (Qiagen). Seventeen tumoral and 2 peritumoral samples achieved an 
optimal RIN (>7) and were processed for further analyses. In addition, 2 new peritumoral samples 
were recruited for the whole genome gene expression analysis (Figure 1). 
Pyrosequencing analysis 
Primers were designed for SYN3, SLC8A1 and GRIA4 using the PyroMark® Assay Design SW 2.0 
(Qiagen) (Supporting Information Table 3). Amplification was carried out using the Platinum® 
Taq (Life technologies). PCR products were purified on the PyroMark Q24 Vacuum Workstation 
according to manufacturer protocol and annealed with the sequencing primer before being run on 
the PyroMark Q24 (Qiagen). Pyrograms were analyzed using PyroMark Q24 Software. 
Whole genome gene expression analysis 
The transcriptome analysis was performed using the HumanHT-12 v4 Expression BeadChip Kit 
(Illumina, San Diego, CA) according to manufacturer’s protocol. The RNA, quantified by 
spectrophotometric (NanoDrop) and fluorometric (PicoGreen) reading, is qualitatively checked by 
means of the tool Bioanalyzer2100 (Agilent Technologies), which provides an index of integrity of 
the RNA (RNA Integrity Number, RIN), ranging between 0 (complete degradation) and 10 
(excellent quality); in our study, were further processed only the samples with RIN>7. 
200 ng of RNA were amplified (Illumina TotalPrep RNA Amplification Kit), labeled and 
hybridized on Illumina microarray. Even with data from transcriptome analysis an Unsupervised 
Hierarchical Clustering is carried out and the expression values are often shown by HeatMap 
qRT-PCR analysis 
Retro-transcription was performed starting from 1μg RNA/sample using the High Capacity Kit 
(Applied Biosystems, Carlsbad, CA, USA). Gene expression was assessed by quantitative RT-PCR 
using Express Sybr Green (Invitrogen, Paisley, UK) for each gene tested and for the endogenous 
TFRC. The primer sequences are reported in Supporting Information Table 3. 
Microsatellite instability analysis 
The microsatellite instability analysis was conducted by using the “MSI Analysis System, Version 
1.2” (Promega Italia). Amplification were carried out according to manufacturer’s protocol. The 
PCR products were then run on an ABI PRISM® 3100 - Applied Biosystems® 3130 Genetic 
Analyzer, and the output data were analyzed with GeneMapper® software (Applied Biosystems). 
Genetic mutations screening 
The genetic mutation screening in adenomas was conducted as previously reported [11,48]. 
To search for KRAS mutations in CRCs, we amplified two fragments corresponding to the exons 2 
and 3 (codon 1-97) (annealing 60 °C). Primer sequences are reported in Supporting Information 
Table 3.  
PCR products were amplified with High-Fidelity Taq polymerase (Platinum® Taq DNA 
Polymerase High Fidelity, Invitrogen), purified (by exonuclease 1 and shrimp alkaline phosphatase) 
and sequenced by fluorescent based Sanger’s direct sequencing in an ABI 3130 DNA capillary 
sequencer. 
CIMP phenotype definition  
To infer a CIMP phenotype definition from the output data obtained by using Infinium® 
HumanMethylation450 BeadChip in the 18 CRCs and 21 adenomas, we referred to the SALSA® 
MLPA® kit (MRC-Holland, Amsterdam, the Netherlands) as reference panel. This ME042-C1 
CIMP MS-MLPA probemix contains 31 MS-MLPA probes which detect the methylation status of 
promoter regions of the following 8 genes: CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, 
NEUROG1, RUNX3 and SOCS1. In the present study, several CpG loci were analyzed for each of 
these gene promoters, mapping inside the MS-MLPA probe sequence. All positions/probes were 
scored using two different thresholds of methylation (≥ 20% or ≥ 30%), as suggested by Berg et al. 
[49] for defining a specific position/probe as methylated. To define a gene as methylated, at least 
one probe/position has to be methylated. To assign the CIMP positivity to a sample, at least 60% of 





The quantile normalization algorithm was applied on the data set. Differential expression analyses 
were carried out between CRCs (T) and peritumoral samples (P). The differential expression is 
given in fold change (FC). False Discovery Rate of 0.05 was chosen as a threshold for significance. 
RNAseq data and differential expression analysis 
To facilitate cross-sample comparison and differential expression analysis, the Upper Quartile 
normalized FPKM (UQ-FPKM) values has been obtained from TCGA open-access data for 478 
CRC solid tumor tissues and 41 solid normal tissues from the GDC (Genomic Data Commons) data 
portal. The data downloading and differential expression analysis has been conducted using the 
Bioconductor “TCGAbiolinks” package [50]. 
qRT-PCR 
Data are expressed as mean ± standard deviation (SD) or mean ± standard error (SEM). Analysis of 
significance was done by t Student’s test and by One-Way ANOVA using the GraphPad software 
(La Jolla, California). P-values were considered significant at p< 0.05. 
 
